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Central nervous system (CNS) infection can induce epilepsy that is often 
refractory to established antiseizure drugs. The Theiler’s murine encephalomyelitis virus 
(TMEV)-induced mouse model of limbic epilepsy is an important model in which to 
study the mechanisms underlying epileptogenesis and to identify novel therapeutics. 
Previous studies have demonstrated the importance of inflammation, especially mediated 
by tumor necrosis factor-α (TNFα), in the development of TMEV-induced acute seizures. 
TNFα is known to modulate glutamate receptor trafficking via TNF receptor 1 (TNFR1) 
to cause increased excitatory synaptic transmission. Therefore, we hypothesized that an 
increase in hippocampal TNFα following TMEV infection might contribute to 
hyperexcitability and seizures by increasing excitatory postsynaptic strength through 
TNFR1. Furthermore, inflammation is known to contribute to oxidative stress that in turn 
can precipitate seizures. Therefore, we also investigated the occurrence of oxidative 
stress in TMEV-infected mice.  
We found a significant increase in the levels of oxidative stress markers and 
TNFα in the hippocampus, a brain region known to be involved in seizure generation, 
following TMEV infection. In addition, a significant increase in the protein expression 
ratio of TNF receptors (TNFR1:TNFR2) in hippocampus suggests that TNFα signaling, 
predominantly through TNFR1, may contribute to limbic hyperexcitability. Consistent 
with increased TNFR1 signaling, increases in hippocampal cell surface glutamate 
iv 
 
receptor expression was also observed during the acute period. While pharmacological 
inhibition of TNFR1-mediated signaling had no effect on acute seizures, several lines of 
transgenic animals deficient in either TNFα or its receptors were found to have robust 
changes in seizure incidence and severity following TMEV infection. TNFR2-/- mice 
were highly susceptible to developing TMEV-induced acute seizures, suggesting that 
signaling through the TNFR2 pathway may provide beneficial effects during the acute 
seizure period. Moreover, cannabidiol (180 mg/kg), which exhibits antiinflammatory and 
antiseizure properties, dramatically inhibited TMEV-induced acute seizures.  
Taken together the present results suggest that oxidative stress and inflammation 
in the hippocampus contribute to hyperexcitability and increase the probability of 
seizures following TMEV infection and that the TNFα signaling pathway is involved in 
this process. Pharmacotherapies designed to suppress inflammation and oxidative stress 
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Central nervous system (CNS) infections are common risk factors for seizures and 
the development of epilepsy. Various infectious agents including viruses, parasites, 
bacteria, and fungi are clinically associated with seizures and epilepsy. The detailed 
cellular and molecular mechanisms of pathological and physiological changes in the 
brain due to acute infection are not clearly understood. Infection induces inflammation in 
the brain which could contribute to the process of epileptogenesis in which normal 
neuronal circuits transform into epileptic circuits which increase the probability of the 
development of epilepsy. A detailed understanding of epileptogenesis following infection 
is of utmost importance for the development of advanced therapies to treat the seizures as 
well as to prevent the progression of disease. Several infection-induced animal models of 
seizure and epilepsy have been described mainly using viral infection and parasitoses in 
rodents. This chapter describes several of them, including those models using herpes 
simplex virus-1, West Nile virus, neurocysticercosis, and Theiler’s virus. We will discuss 
the methods of seizure generation, pathological and physiological changes in the brain, 
                                                 
1 This article was published in Models of Seizure and Epilepsy, Second Edition, in press, 
Dipan C. Patel, Karen S. Wilcox, Postinfectious epilepsy, Copyright Elsevier (2017). 









Infections of the central nervous system are common risk factors for seizures and 
the development of epilepsy. Infections can potentially cause encephalitis (inflammation 
of the brain parenchyma) and encephalopathy (diffuse CNS disease manifested by altered 
consciousness, a range of cognitive and motor neurological symptoms, and systemic 
metabolic disturbances) by directly or indirectly damaging the brain. A broad range of 
infectious agents including viruses (e.g., herpes viruses, enteroviruses, flaviviruses, 
paramyxoviruses), parasites (e.g., Taenia solium, Plasmodium falciparum, Toxoplasma 
gondii), bacteria (e.g., Haemophilus, Streptococcus, Neisseria, Mycobacterium), and 
fungi (e.g., Candida, Cryptococcus) are clinically associated with seizures and epilepsy 
(Vezzani et al., 2016). Among them, viral encephalitis and parasitic infections are the 
most widely reported causes of infection-induced epilepsies in patients. 
Over 100 neurotrophic viruses are known to cause encephalitis in humans and 
many of them may subsequently contribute to seizures and epilepsy. The prevalence of 
viral encephalitis which can be either sporadic or epidemic has been calculated ~7.5 
persons per 100,000 people in the general population (Misra et al., 2008). Herpes simplex 
virus type 1 (HSV-1) is the most common cause of sporadic encephalitis (Theodore, 
2014). Early (acute) seizures can occur in 40-60% of cases of HSV-1 encephalitis which 
is probably due to tropism of HSV-1 for mesial temporal lobe structures, especially 
hippocampus, that are strongly involved in seizure generation and epileptogenesis. A 




determined primary or prior human herpes virus-6B (HHV-6B) and HHV-7 viremia in 
32% and 7% of pediatric patients with febrile status epilepticus, respectively, which is 
associated with increased risk for hippocampal injury and temporal lobe epilepsy 
(Epstein et al., 2012). Japanese encephalitis is the most common form of epidemic 
encephalitis associated with acute seizures, which occur in 7-46% of patients (Misra et 
al., 2008). Viral encephalitis also increases the risk for the development of late (chronic) 
unprovoked/spontaneous seizures. As in acute symptomatic seizures, the development of 
chronic seizures also varies among the types of viral encephalitis; for example, late 
unprovoked seizures occur in 40-65% of patients following HSV encephalitis, while only 
10-12% of La Crosse encephalitis patients go on to develop epilepsy (Misra et al., 2008). 
Other noteworthy viral infections implicated in seizures and epilepsy are human 
immunodeficiency virus (HIV), enterovirus, West Nile virus, measles, 
cytomegaloviruses, influenza viruses, dengue, and chikungunya (Vezzani et al., 2016). 
CNS infection due to parasites can also cause seizures. Major parasitoses 
associated with increased incidence of seizures and epilepsy are neurocysticercosis 
(NCC) and cerebral malaria (CM) notably in low income countries. Up to 10% of African 
children suffering from CM develop epilepsy (Birbeck et al., 2010). CM-associated 
seizures are often focal which may occasionally generalize and ~20% of children present 
with subclinical seizures (Birbeck et al., 2010). 28% of CM patients may develop status 
epilepticus, which is often resistant to antiseizure medications and associated with 
increased neurological disability and mortality rate. NCC is caused by CNS infection of 
the larval stage of tapeworm Taenia solium and it is the most common preventable risk 




NCC develop recurrent seizures and NCC accounts for up to 29% of all epilepsy cases in 
some endemic regions (Ndimubanzi et al., 2010). 
There are fewer clinical cases of epilepsies associated with bacterial infection 
compared to viral infection and parasitoses. However, any bacterial infection of the CNS 
can cause acute seizures and chronic epilepsy. Infections with Haemophilus influenzae 
are more commonly associated with seizures compared to other bacterial infections 
(Stringer, 2006). Acute infection of meninges by Neisseria meningitidis can result in 
acute seizures. After a latent period ranging from several weeks to few years, chronic 
spontaneous seizures, often drug resistant, develop in about 5-10% of survivors of 
meningitis (Oostenbrink et al., 2002). Bacterial infections may induce formation of 
intracranial empyemas and abscesses, and seizures occur in about 35% of patients with 
brain cerebral abscesses and in >50% of patients with dural empyemas (Labar and 
Harden, 1998). Although the cases of fungal infection-induced epilepsy are relatively 
uncommon, many species of fungi including Candida, Cryptococcus, Aspergillus, 
Blastomyces, and Histoplasma have been found to cause seizures, especially in 
immunocompromised people (Vezzani et al., 2016). 
Infection can cause damage to the brain parenchyma by directly infecting the cells 
or by unleashing uncontrolled inflammatory reactions to surrounding tissue. CNS damage 
and excessive inflammation may engender acute seizures and persistent neurological 
abnormalities can result in epilepsy. The detailed mechanisms of neuropathological and 
inflammatory changes due to acute infection and the mechanisms of epileptogenesis as a 
consequence (a process of structural and physiological changes in brain parenchyma 




unknown and it is an active area of research. A detailed understanding of epileptogenesis 
following infection is of utmost importance as it will open the door for novel therapeutic 
approaches to prevent the progression of disease. 
Several infection-induced animal models of seizure and epilepsy have been 
described mainly using viral infection and parasitoses in rodents. This chapter describes 
several of them, including those models using HSV-1, West Nile virus, NCC, and 
Theiler’s virus. The Theiler’s virus model of limbic epilepsy is the most extensively 
studied among all the models with numerous studies published in the last few years 
validating its usefulness for translational studies. We will discuss the method of seizure 
generation, structural and functional changes in the brain, clinical relevance, advantages, 
and limitations of the models. 
 
 
Herpes simplex virus (HSV)-induced model of limbic seizures  
 
HSV-1 is a neurotrophic virus capable of penetrating into brain from intranasal 
route via retrograde axonal pathway and replicating into brain parenchymal cells. It is the 
most common virus clinically associated with seizures and epilepsy. Attempts have been 
made to develop animal models for HSV-1 encephalitis-induced seizures in rabbit 
(Stroop and Schaefer, 1989), rat (Beers et al., 1993; Solbrig et al., 2006), mouse (Wu et 
al., 2003; Wu et al., 2004), and an in vitro system (Chen et al., 2004). 
 
 
Methods of generation  
 
Intranasal or corneal inoculation methods have been used for generating HSV-




Female New Zealand white (NZW) rabbits weighing 2-3 kg are inoculated in each nostril 
with 0.1 ml solution containing 106 TCID50 (50% tissue culture infectious dose) of 
neurovirulent +GC substrain of HSV-1. Similarly, female Lewis rats (around 225 g) are 
infected intranasally with 1.4x106 TCID50 (50% tissue culture infectious dose) of +GC. In 
another rat study, 9 week-old male Lewis rats are infected with 3x106 PFU (plaque 
forming units) of McKrae HSV-1 administered as eye drops in the right eye and 
conjunctival sac followed by closing and opening the eye. For the mouse model, 5-6 
weeks old male BALB/c mice are inoculated with RE strain of HSV-1 ranging from 
2x105 to 2x106 PFU into the right eye by corneal scarification. For in vitro system, 
organotypic cultures of hippocampal slices from Sprague-Dawley rat pups (P10-12) are 
infected with 1x105 PFU of RE at 14 days in vitro for 1 h.  
 
 




NZW rabbits infected with +GC resulted in severe motor seizures in about 59% of 
rabbits (10/17) during 5-12 days postinfection (dpi) (Stroop and Schaefer, 1989). The 
rabbits had the Jacksonial type of seizures lasting for several minutes during each 
occurrence, beginning with muscle movements around nose and mouth which 
sequentially spread to neck, forelimbs and hindlimbs followed by unnatural upright 
posture with nose pointed almost vertically. Electroencephalographic (EEG) 
abnormalities were observed during the first week of infection in two of three rabbits. Of 
the 22 rabbits used overall, all except two rabbits eventually either died or had to be 




Lewis rats infected with +GC developed complex partial seizures which 
secondarily generalized between 7-10 dpi (Beers et al., 1993). Compared to the rabbit 
study, 39% of the rats (9/23) had acute seizures of 30-60 s in duration and only 12% 
(3/26) of the rats died during acute infection. It was not determined if epilepsy developed 
in those rats that survived the infection. Lewis rats infected with McKrae HSV-1 
exhibited Racine stage 1 and 2 limbic focal seizures that did not generalize, although 
long-term EEG recordings were not performed (Solbrig et al., 2006).  
BALB/c mice infected with the RE strain developed progressively worsening 
physical symptoms from ruffled fur, hunched posture, and loss of appetite to limb 
weakness, ataxia, and seizures between 4 and 14 dpi (Wu et al., 2003). Neurological 
deficits, seizures, and mortality varied among infected mice and were correlated with 
viral titer. All the mice with severe encephalitis developed behavioral and EEG seizures 
originating from hippocampus and died by 10 dpi. Only 21% of mice with moderate 
encephalitis had seizures, whereas the mice with mild symptoms of infection did not 
develop seizures. Behavioral seizures started with staring and chewing, and progressed to 
forelimb clonus with/without rearing and generalized tonic-clonic extension. The 





HSV-1 invaded and replicated in the rabbit brain as viral antigens were detected 
in cortical layers IV-VI, trigeminal and olfactory system, amygdala, nucleus accumbens, 
locus ceruleus, and brainstem. The shedding of virus was also detected in ocular and 




mild leptomeningitis, lymphocytic infiltration in medulla, and death of hippocampal 
neurons were found at 6 dpi. The virulence of the virus correlated with its expression 
levels in the brain. 
In Lewis rats infected with +GC, the bilateral inflammatory and hemorrhagic 
lesions and astrogliosis were colocalized with the presence of viral antigens and nucleic 
acids in trigeminal ganglia, olfactory bulbs, piriform and entorhinal cortices, 
hippocampus, and amygdala during the first week of infection. As in the rabbit study, 
shedding of virus in ocular and nasal secretions was also observed. On the other hand, 
inflammatory lesions, gliosis, and viral antigens were not detected in any brain structure 
at 76 and 160 dpi. However, viral nucleic acids were present in the hippocampus and the 
piriform and entorhinal cortices at 76 and 160 dpi suggesting that HSV-1 can establish 
CNS latency in the rat.  
In BALB/c mice infected with RE-HSV-1, the severity of neurological damage 
was highest in the limbic region particularly CA3 of hippocampus, amygdala, entorhinal 
and pyriform cortex, and correlated with the high expression level of viral antigens. 
Infiltration of neutrophils and lymphocytes was detected in hippocampus, pyriform 
cortex, and meninges. Patch-clamp recordings from the CA3 hippocampal neurons during 
7-12 dpi showed more depolarized resting membrane potential, increased membrane 
input resistance, and decreased threshold for bursting activity suggesting that 
hyperexcitability in CA3 neuronal circuitry could facilitate the development of seizures. 
These electrophysiological changes in CA3 neurons were also reported in RE-HSV-1-
infected organotypic hippocampal slice culture. HSV-1-infected mice had an increased 




caused neuronal death and a marked increase in mossy fiber sprouting in the 
supragranular area in slice cultures (Chen et al., 2004). Neuronal loss was ameliorated by 
treating the infected slices with antiviral agent, acyclovir (Chen et al., 2004). Similarly, 
valacyclovir decreased pentylenetetrazole-induced seizure susceptibility in HSV-1-
infected mice (Wu et al., 2004). These results suggest that HSV-1 infection can cause 
hyperexcitability in the hippocampal neuronal circuit leading to seizures and such 





These models are limited by high mortality during the acute infection, although 
the rat model should be investigated for the development of unprovoked chronic seizures 
and epilepsy. HSV-1 also poses other problems with respect to ease of use, as it is known 
to cause diseases in humans and is classified under biosafety level 2 (BSL2) requiring 
regulatory approvals for study.  
 
 
Insight into human disorders 
 
Both rat and mouse models could be useful to study herpes infection-induced 
epilepsies in human as the rodents infected with HSV-1 develop behavioral seizures and 
show clinically relevant neurological lesions and histological changes, especially in the 
temporal region. Therefore, they could be valuable to investigate mechanisms of HSV-1-
mediated seizures. For example, the study investigating the mechanism of seizure 
generation using male Lewis rats infected with McKrae HSV-1 found a decrease in the 




anticonvulsant activity, in the hippocampus (Solbrig et al., 2006). A kappa opioid 
receptor agonist, U50488, effectively blocked ictal activity confirming the antiseizure 
functions of dynorphin. The slice culture model could also be important as it allows high-
throughput screening of potential antiseizure and antiepileptogenic compounds for future 
detailed investigation in animal models (Dyhrfjeld-Johnsen et al., 2010). However, a 
thorough validation of the in vitro system is essential given its drawbacks. 
 
 
West Nile virus (WNV)-induced limbic seizures  
 
WNV is a neurotrophic virus causing epidemic encephalitis often manifested with 




Methods of generation  
 
Adult female C57BL/6 mice aged 8-14 weeks are briefly anesthetized and 
intranasally inoculated with 10 µl of WNV solution in sterile phosphate-buffered saline 
containing 6x104 PFU of virus. 
 
 




Mice are monitored for seizures twice daily until 4 dpi and then every four hours. 
Seizure intensity is recorded based on a summative scoring system ranging from 0 to 12. 
Limbic seizures first appeared on 5 dpi and started with piloerection, tail stiffening, 




handling-induced seizures followed by rearing and falling. Seizure intensity gradually 
increased and all the mice developed limbic seizures. The highest seizure scores were 





Viral antigens first appeared in the olfactory bulb by 3 dpi and subsequently 
spread into cortex and pyramidal neurons of CA1-3 regions of hippocampus on 5 dpi. By 
6 dpi, virus was detected throughout the hippocampus. Thus, the extent of viral 
infiltration and replication in the brain appear to correlate with the induction of seizures 
and gradual increase in the seizure intensity. No histopathological abnormalities were 
detected in the first 3 days of infection. Adhesion of leukocytes to vascular endothelium, 
leukocyte infiltration into the brain parenchyma, and microgliosis were observed at 6 dpi.  
The expression of tumor necrosis factor-α (TNFα) and interleukin-6 (IL-6) in the 
brain were significantly elevated at 7 dpi. However, TNFα-/- mice intranasally infected 
with WNV had limbic seizures comparable to WT mice. The role of interferon-γ (IFNγ) 
was evaluated in detail in this model (Getts et al., 2007). IFNγ-/- mice infected with WNV 
had a significant reduction in seizure intensity and did not have severe limbic seizures, 
indicating that the presence of IFNγ may contribute to seizure progression. The pattern of 
viral infiltration and replication in the brain, neuropathological and inflammatory changes 
including the levels of TNFα and IL-6 were not different between WT and IFNγ-/- mice, 
suggesting that additional factors might be implicated in causing different seizure 








All the mice succumb to infection around 7-8 dpi, thus restricting the use of this 
model to infection-induced acute seizures. 
 
 




NCC is a common helminthic infection of the brain caused by the larval form of 
the tapeworm Taenia solium and is a major cause of seizures and acquired epilepsy 
worldwide. Pigs serve as intermediate reservoir for larval vesicles (metacestode or 
cysticerci) and eggs (containing oncosphere – embryonic form of tapeworm) of T. solium. 
Humans are infected by consumption of raw or undercooked pork or by ingesting food 
and water contaminated with human or animal feces containing T. solium eggs. Eggs 
hatch into larva in the intestines, penetrate the intestinal wall, and migrate to the brain 
where they transform into cycticerci (Stringer, 2006). It can take several years to develop 
clinical symptoms, including seizures, after infection. Altered blood-brain barrier and 
inflammatory reaction around the cysts or associated with calcified granulomas appear in 
patients with NCC-associated seizures, but the factors crucial in causing seizures are 
unclear. Several rodent models of NCC have been developed using mice infected 
intracranially with T. crassiceps (Matos-Silva et al., 2012) or Mesocestoides corti 
(Mishra et al., 2013); however, seizures were not studied in these models. One study 
reported epileptiform activity in a rat model of NCC using granulomas associated with T. 
crassiceps infection (Stringer et al., 2003). In addition, seizures were observed in a 




al., 2015).  
 
 
Methods of generation  
 
As reported in the study by Stringer et al., 2003, female BALB/c mice are first 
inoculated intraperitoneally with T. crassiceps. Live parasites do not cause much 
inflammation but the dying parasites initiate chronic granulomatous reaction in the 
peritoneal cavity. The development of granuloma can be histopathologically graded from 
stage 1-4 with increasing levels of inflammation and tissue damage. Granulomas 
indicative of each stage are isolated from the peritoneal cavity after 3 months of infection 
and the extract of granulomas is injected into the hippocampus or amygdala or other brain 
region of Sprague-Dawley rats (125-175 g) to model NCC. In another model (Verastegui 
et al., 2015), Holtzman rats aged 10-26 days are infected intracranially with activated T. 
solium oncospheres suspended in sterile physiologic salt solution. 
 
 
Characteristics and defining features 
 
Intrahippocampal electrodes are used to record epileptiform activity in the rats 
treated with granuloma extract. All rats injected with the extract from stage 1-2, but not 
stage 3-4, granulomas developed electrographic seizures of average 44 s within 3 min of 
injection. However, subsequent epileptiform activity, spreading of seizures out of 
hippocampus and behavioral seizures were not observed. Neuronal or glial cell loss was 
not detected in the brain. Such findings question the usefulness of this model to study the 
mechanism of epileptogenesis.  




oncospheres at 5 months after infection. The seizures were characterized as generalized 
tonic-clonic and the frequency was at least once a week before necropsy. The presence of 
inflammatory cells and perivascular infiltrate were observed around cysts in cortical and 
subcortical limbic regions. This recent model overcomes some limitations of the previous 
models, but the numbers of rats developing epilepsy are very low. Future studies should 
conduct EEG recordings so as to characterize the seizures that occur as a consequence of 
the development of epilepsy in this model. 
 
 




Theiler’s murine encephalomyelitis virus (TMEV) is a single-stranded positive-
sense ribonucleic acid (RNA) virus belonging to Picornaviridae family and Cardiovirus 
genus. Several strains of TMEV have been characterized based on their neurovirulence. 
They are primarily grouped into two categories: 1) TO (Theiler’s original) and 2) GDVII. 
The TO group contains less neurovirulent strains such as TO, DA (Daniels), BeAn8386 
(BeAn), and WW; whereas the GDVII group contains highly neurovirulent strains 
including GDVII and FA. Mice infected with the TO group of TMEV strains generally 
survive the infection and exhibit a variety of pathological changes depending on the 
strain of both virus and mice, and therefore, they are useful to model several different 
diseases. C57BL/6J mice infected with the DA strain of TMEV develop acute seizures 
during the first two weeks of infection and develop limbic epilepsy after about two 






Methods of generation 
 
Five to seven weeks old C57BL/6J (B6) mice are briefly anesthetized with 3% 
isoflurane and infected with 20 µl of DA-TMEV solution intracortically in the right 
hemisphere by inserting the needle at a 90° angle to the skull. The injection region is 
located slightly medial to the equidistant point on the imaginary line connecting the eye 
and the ear. A sterilized syringe containing a plastic jacket on the needle exposing 2.5 
mm of needle is used for infection to restrict the injection site to the somatosensory 
cortex without damaging the hippocampus. The schematic in Figure 1.1 summarizes the 
timeline of TMEV infection and the development of acute and chronic seizures. 
 
 




Generally, 5-7 weeks old mice are used for TMEV infection. However, 3 months 
old mice have also been observed to respond similarly to TMEV infection-induced 





TMEV-induced seizure patterns are similar among male and female mice (Libbey 





Development of seizures is C57BL/6J strain-specific. SJL/J (male and female), 









Mice develop acute behavioral seizures from 3-10 dpi. Handling the mice or 
mildly agitating the cages induces seizures during the acute infection period. Seizures 
follow a pattern of focal onset with secondarily generalized tonic-clonic seizures and the 
seizure severity can be characterized by a modified Racine scale from stage 1 to 6 where 
stage 1 – mouth and facial movement, stage 2 – head nodding, stage 3 – forelimb clonus, 
stage 4 – forelimb clonus, rearing, stage 5 – forelimb clonus, rearing, and falling, and 
stage 6 – intense running, jumping, repeated falling, and severe clonus (Racine, 1972). 
Generally, mild seizures (stage 1-3) appear in about 25-50% of the infected mice by 3 
dpi. As the infection progresses, additional mice develop seizures and the seizure 
intensity and duration steadily increases (stage 4-6) by 5 dpi. Numbers of seizures 
gradually decrease after 5 dpi without reduction in the intensity and most of the mice 
cease to have seizures by 8 dpi (Bhuyan et al., 2015). Mice do not generally develop 
status epilepticus during the acute infection period. 
Seizures are afebrile in nature and their properties, including frequency, intensity, 
duration, and latency to first appearance, vary among mice. The percentage of infected 
mice developing seizures is positively correlated with the titer of DA-TMEV used for 
infection. A dose-response study demonstrated that seizure incidence increased from 30% 
with 3x103 PFU, to 40% with 3x104 PFU, to 65% with 3x105 PFU, and to 80% with 
3x106 PFU (Libbey et al., 2011b). Mice experience 10-15% weight loss during acute 




infection period with varying symptoms of hunched posture, lethargy, decreased 
locomotion, and ruffled fur; however, mortality is very rare. Mice clear the virus from the 





A long-term continuous video encephalography (vEEG) study in mice surgically 
implanted with a recording electrode on the cortical surface 10-14 days before infection 
have been used to detect and monitor seizures (Figure 1.2) (Stewart et al., 2010a). 
Electrographic seizures are characterized as rhythmic spikes or sharp-wave discharges 
with amplitudes at least 2 times higher than baseline and lasting longer than 6 s and are 
associated with convulsive seizures (Figure 1.2). In this study, 75% (12/16) of mice were 
found to have seizures by vEEG monitoring compared to an incidence of only 52% 
(54/103) by twice-daily observations during the first 2 weeks of infection with 2x104 
PFU per mouse (Libbey et al., 2008; Stewart et al., 2010a). This first vEEG study 
reported average seizure incidence of 14.5 ± 10.5 (mean ± SD) seizures per mouse and an 




Chronic seizures and epilepsy 
 
Chronic spontaneous seizures and the development of epilepsy have been studied 
by vEEG up to 8 months post-TMEV infection (Stewart et al., 2010a). In this study, 14 
mice which had acute behavioral seizures detected by visual observation in the first two 




postinfection. The continuous vEEG recordings conducted at 2-months postinfection for 
one week, and at 4 and 7 months postinfection for one month each detected 
electrographic seizures accompanied by stage 4-5 behavioral seizures in 9/14 (64%), 4/7 
(57%), and 2/5 (40%) mice, respectively. All mice had epileptiform activity defined as an 
abnormal electrographic activity characterized by large amplitude, multispike 
morphology and either associated with sudden cessation of activity or no distinct 
behavioral correlate. Chronic seizure frequency was 2.1 seizures per mouse per week at 2 
months and <1 seizure per mouse per week during the 5th- and 7th-month recording 
periods. A more recent vEEG study also demonstrated that all infected mice exhibit 
epileptiform EEG activity well after the infection has cleared and early seizures have 
resolved (Broer et al., 2016). In addition, this group also found that DA-TMEV infection 
results in spontaneous recurrent seizures in about 38% of the mice examined (Broer et al., 





Localization of TMEV in the brain  
 
Many viruses associated with seizures exhibit tropism for neurons in limbic brain 
structures (Misra et al., 2008). The DA-TMEV strain has also been shown to infect 
primarily neurons in the limbic and temporal regions of B6 mice. TMEV antigens can be 
detected bilaterally in the hippocampus, septal nuclei, periventricular thalamic nuclei, and 
parietal, piriform, and entorhinal cortices of B6 mice during 3-7 dpi (Stewart et al., 
2010b). Pyramidal neurons of the CA2 and CA1 region of the hippocampus are highly 




usually devoid of TMEV antigens. TMEV is largely undetectable in the brain by 14 dpi. 
Antigens of DA-TMEV have also been found in the brainstem at 2 dpi (Buenz et al., 
2009). The cell surface receptor(s) that TMEV uses for insertion into the cells has not 
been determined, but sialic acid (carbohydrate co-receptor) has been implicated in 
cellular attachment of DA-TMEV (Lipton et al., 2006). 
 
 
Inflammation following infection  
 
Infection in the host is known to induce a variety of defense mechanisms that are 
intended to fight the infectious agents. However, the immune defense is akin to a double-
edged sword. Optimal functions of the immune system are desirable; whereas excessive 
and prolonged activation of immune mediators can cause autoimmune inflammatory 
conditions and tissue damage. Several studies investigating the role of immune cells and 
molecules have been conducted in the TMEV model of epilepsy. These studies were 
aimed to address the following key important questions regarding this model: 1) do the 
infection-induced inflammatory conditions in the brain primarily drive the seizure 
activity and/or is the inflammation actually a consequence of seizure activity; 2) what is 
the relative contribution of the cells of the innate and adaptive immune system in seizure 
induction; and 3) do the neurological changes and seizure development accompanying 
TMEV infection recapitulate the clinical findings from patients suffering from infectious 









Role of innate immune system 
 
The innate immune system is the first line of defense against tissue damage 
caused by mechanical, chemical, or biological insult. A temporally and spatially 
regulated well-coordinated response comprised of a variety of proteins including 
cytokines, chemokines, complement proteins, growth factors, adhesion molecules, and 
intracellular signaling components rapidly develops upon stimuli such as infection and 
even seizures. The cell types implicated in driving the acute immune response in the CNS 
are microglia, astrocytes, endothelial cells of the blood vessels, and the immune cells of 
the peripheral compartment (macrophages, neutrophils, natural killer cells, and dendritic 
cells) that can infiltrate into the central compartment due to compromised blood-brain 
barrier and sometimes neurons. 
TGFβ (transforming growth factor-β).  Initial studies measured the level of TGFβ 
in the brain after infection because activation of the TGFβ signaling pathway contributes 
to seizure generation and epileptogenesis during and following CNS injury (Cacheaux et 
al., 2009). A significant increase in the level of TGFβ was found in the hippocampus 
from 5-7 days post-TMEV infection in seized mice (Libbey et al., 2008). TGFβ was 
highly expressed in the pyknotic neurons in the pyramidal layer of hippocampus and less 
extensively in the cortical neurons. Activation of TGFβ signaling in astrocytes in blood-
brain barrier injury models of epilepsy contributes to astrocyte dysfunction and the 
impairment in the regulation of neuronal functions underlying the development of 
epilepsy (Vezzani et al., 2011). Interestingly, losartan, which is known to inhibit 
peripheral TGFβ signaling, significantly reduced the numbers of rats developing chronic 




vascular injury. This study provides evidence that TGFβ signaling could be targeted as a 
potential antiepileptogenic strategy. The validity of this strategy should be evaluated in 
the TMEV infection-induced model of epilepsy. 
Cytokines.  IL-1, IL-6, and TNFα are among the most widely investigated 
cytokines in various animal models of epilepsy as well as in clinical studies (Vezzani et 
al., 2008). The constitutive protein levels of these cytokines in the brain are normally 
barely detectable but they rapidly increase following seizure-inducing stimuli.  
In the TMEV model, analysis of messenger RNA (mRNA) expression of 
cytokines – IL-1, IL-6, and TNFα – in the whole brain lysate at 6 dpi showed an increase 
in the levels of IL-1β in the seized mice (16-fold) and in the nonseized mice (9-fold), 
whereas the levels of IL-1α was increased by 4.3-fold in the seized mice and by 4.7-fold 
in the nonseized mice (Kirkman et al., 2010). TNFα level was dramatically increased by 
128.5-fold in mice having acute seizures and by 13.5-fold in TMEV infected mice 
without seizures. IL-6 levels were also significantly increased by 67-fold in the seized 
mice and 44.5-fold in the nonseized mice. There was no difference in the mRNA levels 
of IL-1 and TNFα at 2 dpi before the induction of the first seizure. These data suggest an 
association between the mRNA levels of cytokines, especially TNFα and IL-6, and the 
acute seizure activity. To confirm the contribution of these cytokines in the development 
of seizures, mice strains deficient either in these cytokines or their receptors or signaling 
protein were tested for their seizure response following TMEV infection (Kirkman et al., 
2010). Both IL-1α and IL-1β bind to IL-1R and initiate signaling via the adaptor protein 
known as myeloid differentiation primary response gene 88 (MyD88). About 38% of IL-




first two weeks of infection compared to 52% of WT mice (n = 103). These effects were 
not statistically significant. In contrast, only 15% of IL-6-/- mice (n = 20) and 10% of 
TNFα receptor 1-/- mice (TNFR1-/-, n = 20) developed seizures compared to the control 
group. It is concluded from these experiments that IL-1 signaling via IL-1R and MyD88 
may not be involved in seizure induction in TMEV model, whereas TNFα and IL-6 
signaling contribute significantly in seizure generation during the acute infection period. 
The fact that IL-1-mediated signaling is not strongly implicated in TMEV-
induced seizures is surprising, as IL-1β has been established by studies from multiple 
groups as an important cytokine that underlies proconvulsant effects in various animal 
models of epilepsy (Vezzani et al., 2011). The animal studies exploring the functions of 
IL-6 in seizure generation present dichotomous results (Campbell et al., 1993; Penkowa 
et al., 2001). Similarly, studies in other animal models of epilepsy have shown either 
proconvulsive or anticonvulsive effects of TNFα. TNFα is a pleiotropic cytokine having 
important functions in inflammation and immunoregulation. TNFα exerts its effects via 
two receptors: TNFR1 and TNFR2. The effects of TNFα on neural circuit function 
depends on various factors, including relative expression levels of TNFRs (TNFR1 and 
2) in the tissue and the cell types expressing them (McCoy and Tansey, 2008). Indeed, 
TNFR1-mediated signaling has been implicated in causing hyperexcitatory and ictogenic 
effects of TNFα, whereas TNFR2 mediated antiseizure effects of TNFα in rodents treated 
with kainic acid (Balosso et al., 2005; Weinberg et al., 2013). Further studies should 
thoroughly investigate the roles of these cytokines in acute and chronic seizure 
development in the TMEV model. The mRNA levels were measured in the whole brain 




the hippocampus, which is the epicenter of TMEV-induced damage and a likely region of 
seizure initiation. The contributions of the TNFRs in seizure generation should also be 
evaluated in the future.  
In conclusion, inflammation mediated by cytokines, especially TNFα and IL-6, 
appears to contribute significantly in the development of acute seizures in the TMEV 
model. Cytokines can modulate neurotransmission by affecting the levels of excitatory 
and inhibitory neurotransmitters and their receptors, enzymes involved in the metabolism 
of neurotransmitters, and cellular signaling proteins (Wilcox and Vezzani, 2014). 
Hyperexcitable conditions and seizures can cause neurotoxicity which could in turn fuel 
the inflammatory process and contribute to the process of epileptogenesis. However, 
inflammation is also crucial to clear the viral infection, and therefore, some functions of 
cytokines in the TMEV model are likely to be beneficial and this needs further 
investigation. There must be a tightly regulated threshold in the level of inflammation, 
and violation of that threshold due to impaired regulatory processes could “prime” the 
neuronal circuits for hyperexcitation and development of either acute or chronic 
spontaneous seizures. 
The complement system.  The complement system is another component of the 
innate immune system that recognizes and eliminates pathogens through direct cell lysis 
and mobilizing innate and adaptive immunity (Ricklin et al., 2010). It is comprised of 
several serum proteins synthesized in the CNS by neurons, glia, and blood endothelial 
cells (Alexander et al., 2008). The expression of complement component proteins 
increases after viral infection primarily in microglia and macrophages. The activation of 




(Zhang et al., 2007). Therefore, the role of the complement system in seizure 
development was also recently evaluated in the TMEV model. 
The mRNA level of C3 was increased over 100-fold at 6 dpi in the brain of 
TMEV-infected mice, both with or without behavioral seizures (Kirkman et al., 2010). 
Interestingly, only 17% of C3-/- C57BL/6J mice (n = 41) had behavioral seizures in the 
first 3 weeks of TMEV infection compared to 52% in WT C57BL/6J mice (n = 103), 
indicating that C3 is involved in seizure generation in this model (Kirkman et al., 2010). 
About 40% of C57BL/6J mice (n = 22) pretreated with cobra venom factor to deplete C3 
in the periphery developed behavioral seizures during acute TMEV infection, which was 
comparable to WT C57BL/6J mice (Kirkman et al., 2010). These data along with 
increased mRNA level of C3 in the brain indicate that the increased expression of C3 in 
the CNS is implicated in seizure generation in the TMEV model. The contribution to 
seizure induction by C3 could be either directly, by manipulating the synaptic functions 
in the CNS, and/or indirectly by increasing the release of TNFα or IL-6. 
Chemokines.  Chemokines are specific types of cytokines that are important for 
chemotaxis and recruitment of various immune cells in the blood to the sites of infection 
or injury. The mRNA expression of several chemokine ligands and receptors involved in 
the recruitment of polymorphonuclear granulocytes (PMNs), macrophages/monocytes, 
and natural killer (NK) cells were found to be elevated in the brains of TMEV-infected 
mice with seizures at 6 dpi compared to PBS-injected control mice (Libbey et al., 2011a). 
This study did not clearly correlate the particular type of infiltrating cell with the 
development of acute behavioral seizures because there are overlapping functions of 




that infiltrating immune cells from the peripheral compartment could be important in the 
regulation of seizures. 
Other inflammatory proteins.  The functions of other inflammatory mediators 
such as toll-like receptors, adhesion molecules, prostaglandins, interferons, and 
inflammatory signaling proteins, for example, nuclear factor kappa-light-chain-enhancer 
of activated B cells (NF-κB) and mammalian target of rapamycin (mTOR), which are 
implicated in the development of seizures and epilepsy in some experimental animal 
models and in some human epilepsies, are not clear in the TMEV model and warrant 
future investigation. 
Immune cells of innate immunity.  Cells of the innate immune system include 
PMNs (neutrophils, basophils, and eosinophils), macrophages, monocytes, NK cells, and 
dendritic cells in the peripheral compartment. In the CNS, glial cells (microglia and 
astrocytes) are particularly involved in innate immune response. These cells are 
“activated” under pathogenic conditions and are known to release cytokines in order to 
neutralize the threat or insult.  
Gliosis, which is the activation of glial cells in response to CNS injury, has been 
observed in mice during TMEV-infection (Loewen et al., 2016). Immunohistochemical 
analysis has revealed a significant increase in Ricinus communis agglutinin-I-positive 
cells (marker for activated microglia/macrophage) at 5, 7, 14, 21, and 35 days post-
TMEV infection and in glial fibrillary acidic protein (GFAP)-positive cells (marker for 
activated astrocytes) at 7 and 14 days post-TMEV infection in the brains of mice with 
seizures compared to nonseized and PBS-injected mice (Kirkman et al., 2010). Gliosis 




immunoreactivity for ionized calcium-binding adapter molecule 1 (IBA-1, another 
marker for activated microglia) and GFAP in the hippocampus of TMEV-infected mice 
during and after behavioral seizures during the acute infection period (4 and 14 dpi) 
(Loewen et al., 2016). Glial proliferation also occurs in the hippocampus of TMEV-
infected mice during seizures (4 dpi). Astrogliosis was also found in the hippocampus at 
4-6 months post-TMEV infection (Stewart et al., 2010a), suggesting that although TMEV 
is cleared from the CNS within 2 weeks of infection, chronic inflammatory conditions are 
sustained in the brains of TMEV-infected mice that had acute seizures. Further studies 
should elucidate the network consequences of long-term astrogliosis in the TMEV-
infected mice. 
Activated microglia, astrocytes, and infiltrating immune cells in the TMEV-
infected brain could be involved in seizure development through increased production 
and release of cytokines, especially TNFα and IL-6. Mice treated with minocycline 
during the first week of TMEV infection to inhibit activation and recruitment of 
monocytes/macrophages and activation of microglia were significantly less susceptible to 
developing acute seizures compared to vehicle treated mice (Libbey et al., 2011a), 
supporting the role of both CNS and peripheral immune cells in seizure development. 
The relative contribution of resident CNS cells versus infiltrating cells in the 
development of seizures was studied by inhibiting activation and/or infiltration of 
particular peripheral immune cell in the CNS. The numbers of mice developing acute 
seizures in the first 3 weeks of infection were not significantly different in mice 
pretreated with either anti-Gr-1 antibody (targeting neutrophils, 50% seized, n = 20), or 




(targeting NK cells, 40% seized, n = 15) compared to control mice (61% seized, n = 28) 
indicating that PMNs especially neutrophils and NK cells may not be instrumental in the 
development of seizures (Libbey et al., 2011a). These experiments along with gliosis 
studies show that infiltrating macrophages/monocytes, microglia, and astrocytes may be 
involved in TMEV-induced seizure development. 
The contribution of infiltrating macrophages/monocytes and glial cells in 
inducing the release of TNFα and IL-6 has been addressed using chimeric mice. Wildtype 
and IL-6-/- C57BL/6J mice were lethally irradiated to destroy the bone marrow, and were 
transplanted with bone marrow cells from either WT or IL-6-/- donor mice to generate 
chimeric mice that were deficient in IL-6 specifically either in the CNS (WT→IL-6-/-) or 
in the periphery (IL-6-/-→WT) (Libbey et al., 2011a). Only 25% of WT→IL-6-/- mice (n = 
16) and 17% of IL-6-/-→WT mice (n = 18) developed behavioral seizures compared to 
65% of age-matched WT control mice (n = 40), implicating IL-6 production by both 
resident CNS cells and infiltrating cells in the development of seizures. TMEV infection 
was conducted at 3 months of age for this experiment instead of the usual age of 4-7 
weeks, suggesting that the older mice are also similarly susceptible to TMEV-induced 
seizures. Similarly, the experiments using lethally irradiated WT C57BL/6J mice 
transplanted with GFP+ bone marrow cells, in which the majority of infiltrating 
macrophages, but not microglia, were GFP-labelled, showed a significant increase in the 
infiltration of macrophages in the brain following TMEV infection (Cusick et al., 2013). 
Flow cytometric analysis of the brain samples from TMEV-infected GFP+ chimeric mice 
revealed significantly higher numbers of GFP+ macrophages labelled with IL-6, whereas 




and IL-6 are produced by resident microglia and infiltrating macrophages, respectively 
(Cusick et al., 2013). 
 
 
Role of adaptive immune system 
 
The roles of B cells and CD4+ T cells have not been elucidated in the TMEV 
model. CD8+ cytotoxic T cells were detected around the perivascular cuffs in the 
hippocampus of TMEV-infected mice with and without acute seizures during 5-7 dpi 
(Libbey et al., 2008). The extent of perivascular cuffing and the infiltration of T cells 
were similar between seized and nonseized mice, indicating that T cells may not be 
implicated in seizure induction per se, but they could be involved in the clearance of 
viral-infected cells. The contribution of cytotoxic T cells in viral clearance and in the 
development of acute seizures was investigated using OT-I transgenic mice in which the 
majority of CD8+ T cells are highly specific for detecting ovalbumin. The seizure 
susceptibility of OT-I and WT C57BL/6J mice was similar during acute TMEV infection 
which suggests that the TMEV-specific CD8+ T cells do not modulate seizure activity 
(Kirkman et al., 2010). Similar to WT mice, acute seizures resolved in OT-I mice after 10 
dpi. However, both RNA and protein of virus were detected in the brains of TMEV-
infected OT-I mice with and without seizures during 12-17 dpi, whereas WT mice clear 
the virus from the brain by 14 dpi (Kirkman et al., 2010). This suggests that the 
persistence of virus in the brain is not correlated with observable seizure activity. The 
innate inflammatory immune response directed against viral infection, and subsequently 
intensified due to seizures, is one of the most probable driving factors causing TMEV-








Oxidative stress  
 
Increased levels of cytokines, chemokines and other inflammatory mediators in 
response to TMEV infection can directly damage mitochondria, resulting in oxidative 
stress. In addition, oxidative stress can facilitate seizure generation by damaging the 
neurons and intensifying the inflammatory processes. Cross-talk between inflammation 
and oxidative stress could be involved in the development of seizures following TMEV 
infection. TMEV-infected mice have a significant reduction of reduced glutathione 
(GSH) and a concomitant increase in oxidized glutathione (GSSG) in the hippocampus 
during acute seizures that persists after cessation of seizures (Bhuyan et al., 2015). The 
GSH and GSSG levels were similar between infected and control mice before the 
induction of seizures. The ratio of 3-nitrotyrosine/tyrosine (3NT/Tyr) which is a marker 
for reactive oxygen and nitrogen species was also increased at 3, 4 and 14 dpi (Bhuyan et 
al., 2015). There was no change in these markers of oxidative stress in the cerebellum. 
These data suggest that oxidative stress occurs in the TMEV model concurrently with 
inflammation and acute seizures and may prove to be an important therapeutic target for 
treatment of acute seizures and perhaps even the process of epileptogenesis. 
 
 
Neural injury  
 
TMEV exhibits tropism for limbic structures of the brain and, as mentioned 




Neuronal death occurs bilaterally in the neurons of the CA1/CA2 pyramidal layer of 
hippocampus, entorhinal and parietal cortices, and periventricular thalamic nuclei during 
acute infection (Stewart et al., 2010b), thus, overlapping in the areas with the presence of 
virus. However, the cell death may not be exclusively due to virus itself. In fact, one 
study found that majority of degenerating hippocampal neurons were not infected with 
TMEV and the authors concluded that CA1 pyramidal neurons die as “bystanders” 
(Buenz et al., 2009). Inflammation, oxidative stress, and seizures may all contribute to the 
observed neuronal damage. Hippocampal neurodegeneration and sclerosis result in 
significant bilateral hippocampal atrophy and coincident increase in the size of the lateral 
ventricles as early as 1 month postinfection (Stewart et al., 2010a). Other 
neuropathological changes that have been described in the hippocampus during acute 
infection include perivascular cuffs (accumulation of leukocytes around vessels that is 
commonly observed in viral encephalitis) and pyknosis (chromatin condensation in 
necrotic cells) (Libbey et al., 2008). Demyelination in the spinal cord, which occurs in 
SJL mice infected with DA-TMEV, does not occur in TMEV-infected C57BL/6J mice 
(Stewart et al., 2010b). 
 
 
Neurophysiological changes  
 
Acute seizures that occur with viral encephalitis are associated with an increased 
risk of developing chronic spontaneous seizures. The hyperexcitability in TMEV-infected 
mice was assessed by seizure threshold tests and corneal kindling at 2 months 
postinfection (Stewart et al., 2010b). The seizure thresholds for limbic and forebrain 




achieve the fully kindled state were significantly reduced in TMEV-infected mice which 
indicate that TMEV-infected mice with acute seizures have a hyperexcitable neural 
circuit in the forebrain and limbic structures which is associated with an increased 
susceptibility to develop chronic seizures.  
A significant increase in c-fos staining, a marker for increased neuronal activity, 
was observed in CA1-3 and dentate gyrus regions of hippocampus of TMEV-infected 
mice within 2 h of acute seizures (Smeal et al., 2012). These findings suggested that the 
hippocampus of TMEV-infected mice was involved in seizure generation and/or spread. 
Subsequent patch-clamp recordings of CA3 pyramidal cells were consistent with the 
findings of c-fos expression by revealing a significant increase in the amplitude and 
frequency of spontaneous excitatory postsynaptic currents (sEPSCs) during the acute 
infection (3-7 dpi) as well as 2 months postinfection (Smeal et al., 2012). The amplitude 
and frequency of miniature EPSCs (mEPSCs) in the CA3 cells were also significantly 
increased during both time points, suggesting that the excitatory synaptic changes occur 
early during the infection and can be sustained for a long time. CA3 cells receive 
excitatory input from the mossy fibers from the dentate gyrus, recurrent collateral 
connections of CA3 cells, and also via the perforant path from the entorhinal cortex. The 
increases in the larger amplitudes of mEPSCs (>20 pA), which are known to have mossy 
fiber origin (Henze et al., 1997), were similar between acute and chronic time points. The 
proportion of mEPSCs of 11-20 pA, associated with CA3 recurrent collaterals, was 
significantly increased during acute infection and decreased during 2 months 
postinfection. The different pattern of changes in mEPSC amplitudes suggests that the 




and may reflect different seizure generating or sustaining circuits at the later time point. 
A recent patch-clamp study in CA3 pyramidal cells also shows a reduction in the 
amplitudes of spontaneous as well as miniature inhibitory postsynaptic currents (sIPSCs 
and mIPSCs) during the acute infection period (3-7 dpi) but not at 2 months postinfection 
(Smeal et al., 2015). From a mechanistic standpoint, TNFα seems to provide a key 
contribution in acute seizure development in the TMEV model. TNFα signaling has been 
shown to increase the membrane insertion of glutamate receptors and to decrease 
membrane expression of GABAA receptor subunits (Stellwagen and Malenka, 2006). 
Thus, it is possible that TNFα-mediated synaptic scaling might contribute to 
hyperexcitation in the CA3 circuit during acute TMEV infection. However, it is crucial to 





TMEV-infected mice display impairment in motor functions and coordination. 
TMEV-infected mice have a significant righting reflex deficiency during the acute 
infection period (Libbey et al., 2008). Following the acute infection period, TMEV-
infected mice show anxiety-like behavior as observed by their impaired performances in 
open field and light-dark box tests (Umpierre et al., 2014). While TMEV-infected mice 
do not have apparent signs of depressive-like behavior in a saccharin preference test 
(Umpierre et al., 2014), they were cognitively impaired in a novel object place 
recognition task and in the Morris water maze test. Impairment in spatial memory in 
TMEV-infected mice was also reported by another research group (Buenz et al., 2006) 




Use in therapy and biomarker development 
 
Efforts are currently ongoing to incorporate the TMEV model into the repertoire 
of animal models used for the National Institute of Neurological Disorders and Stroke 
(NINDS)-sponsored Epilepsy Therapy Screening Program. Recently, the efficacy and 
disease-modifying potential of carbamazepine (CBZ) and valproic acid (VPA) was 
assessed in the TMEV model (Barker-Haliski et al., 2015). VPA (200 mg/kg) and CBZ 
(20 mg/kg) given twice daily during the first week of TMEV infection did not decrease 
the proportion of mice developing acute seizures, although VPA reduced the seizure 
burden. CBZ, in fact, increased the numbers of mice developing seizures and the 
concomitant seizure burden, and decreased the latency to first seizure. Treatment with 
either drug did not improve anxiety-like behavior associated with TMEV-infected mice. 
However, this study did not assess the ability of early treatment with these drugs to 
prevent the subsequent development of chronic spontaneous seizures. In addition, as 
mentioned earlier, the mechanisms driving provoked and spontaneous seizures in this 
model are likely to be different, and CBZ and VPA may have different effects on the 
seizures that occur after epilepsy develops. Inflammation plays an instrumental role in 
seizure development in the TMEV model. Indeed, minocycline and wogonin, which 
decrease inflammation by suppressing activation of microglia/macrophages and 
infiltration of macrophages in the CNS, were both found to reduce TMEV-induced acute 
seizures (Cusick et al., 2013). Thus, this model provides the opportunity to study the 
etiologically relevant epileptogenesis mechanisms to identify novel classes of therapies to 
prevent seizures as well as the epileptogenesis process.  




TMEV model highlights a challenge for using chronic seizures as an outcome measure 
for drug development. Alternatively, predictive biomarkers such as reduced seizure 
thresholds, behavioral comorbidities such as anxiety-like behavior and cognitive 
performance, or changes in the levels of inflammatory proteins, may prove useful to 





The TMEV model is not technically challenging to establish and has been 
successfully replicated (Broer et al., 2016). TMEV is a natural pathogen of mice, and it 
does not infect humans and is not known to cause any adverse human health issues. 
Therefore, the TMEV model does not pose specific challenges to the researchers. Finally, 
because the strain of mouse used (C57BL/6) is the common background on which many 
transgenic mouse models are generated, it is possible to use powerful genetic 
manipulations to test hypotheses relevant to epileptogenesis in this model. 
 
Limitations and model optimization considerations 
 
While clearly this first model of infection-induced TLE is an important model of a 
common cause of human TLE, the frequency and incidence of spontaneous seizures after 
the virus clears are fairly low. Thus, the detailed studies of epileptogenesis and drug 
treatment in the later time period would require a very large cohort of mice monitored by 
24/7 vEEG for prolonged periods of time. However, the numbers of mice developing 
seizures during the acute infection period are correlated with TMEV titer and the initial 




PFU of TMEV. Future experiments should investigate whether the development of 
subsequent TLE following infection with a higher titer of TMEV increases the incidence 
of seizures. In addition, focal seizures without a behavioral correlate may have been 
missed in the original report. Therefore, subsequent studies using hippocampal depth 
electrodes may provide additional outcome measures (e.g., interictal spiking, 
hippocampal paroxysmal discharges, etc.) that can be quantified and associated with the 
development of TLE. 
 
 
Insight into human disorders 
 
TMEV-infected mice exhibit seizures during the acute infection period, survive 
the infection, clear the virus, develop spontaneous seizures, and show evidence of 
inflammation, neuropathological abnormalities, and behavioral and cognitive 
comorbidities (Table 1.1). Thus, the TMEV model mimics many aspects of seizures that 
occur in patients during and following infection and provides a unique opportunity to 
study mechanisms of infection-induced seizures, subsequent epileptogenesis, and 
behavioral comorbidities.  
The nature of neuropathological changes in the brain and the involvement of 
numbers of inflammatory markers in seizure development following TMEV infection 
substantiates that the TMEV model could be a relevant model for human mesial TLE. 
First, the limbic region is a critical area of the brain in patients with TLE, as epileptiform 
and ictal activity, as well as pathological damage, have been observed (Sharma et al., 
2007). Second, many studies in human epilepsy patients have reported increases in the 




in surgically resected brain tissues (Vezzani et al., 2011). The complement system has 
also been suspected to contribute to seizures and epileptogenesis in patients with mesial 
TLE (Aronica et al., 2007). Third, there is evidence of oxidative stress in patients with 
TLE (Rowley and Patel, 2013). Finally, activation of microglia, astrocytes, macrophages, 
and PMNs has been reported in human epilepsy cases (Vezzani et al., 2011). Despite 
these useful clinical reports, it is important to mention that the human studies are 
constrained by the limited availability of sufficient brain samples and appropriate control 
samples for biochemical and physiological analysis and therefore, they often involve 
measuring the levels of inflammatory molecules in the serum. Thus, these data may not 
be sufficient to establish a cause-and-effect relationship between the increased levels of 
inflammatory molecules and the seizure activity. Nevertheless, it is evident that 
inflammatory markers are present at high levels in epileptic patients, thus warranting in-
depth investigation where TMEV model could be useful to understand how excessive 
inflammation affects neuronal functions to cause seizures. 
The prevalence of neurological and psychiatric disorders such as anxiety, 
depression, cognitive impairment, and migraine is significantly higher in patients with 
epilepsy than in the general population (Brooks-Kayal et al., 2013). Antiseizure 
medications can suppress seizures but do not generally treat the cognitive and behavioral 
comorbidities associated with epilepsy. A detailed study of the mechanisms of 
comorbidities in experimental models is necessary to develop new therapies which not 
only decrease seizures but also improve the quality of the patient’s life. Since the TMEV 
model reflects several clinically relevant behavioral comorbidities, it provides an 









Animal models of epilepsy have been enormously useful in generating 
fundamental knowledge about the changes at the genetic, molecular, cellular, and circuit 
levels in the brain during seizures and epileptogenesis. This knowledge has been crucial 
in successfully discovering and developing many antiseizure drugs. Despite having 
numerous animal models for epilepsy and over 20 approved antiseizure drugs, around 
one third of epilepsy patients are still pharmacoresistant (Loscher and Schmidt, 2011) and 
many of these patients have epilepsy that is the result of CNS infection. A limitation of 
previous antiseizure drug discovery efforts may be that similar and conventional animal 
models were used, without necessarily considering the underlying disease-modifying 
mechanisms underlying the development of epilepsy in patients. The heterogeneous 
nature of epileptogenesis in patients suggests that there is a clear need for better animal 
models that more closely recapitulate clinical events. Therefore, valuable progress has 
been made in the past 10 years in developing the etiologically relevant animal model of 
infection-induced epilepsy that is described here. It is expected that the TMEV model, as 
well as other infection-induced models of epilepsy, will fill a void by providing a better 
understanding of the mechanism(s) of epilepsy and by providing a discovery platform 
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Figure 1.1 Schematic of the TMEV-infection mouse model of temporal lobe epilepsy. 
C57BL/6J mice are infected with Theiler’s murine encephalitis virus or sham (PBS, 
phosphate-buffered saline) and monitored for acute and chronic seizures as described in 
the chapter. TMEV-infected mice present with acute behavioral seizures between 3 to 10 
days postinfection and survive the infection. Mice then undergo the process of 
epileptogenesis during the latent period. Mice develop late spontaneous seizures after 








Figure 1.2 Electroencephalographic (EEG) recording from TMEV-infected mice. An 
example of EEG recording from an electrode implanted on the cortical surface of TMEV-
infected mouse is shown during an acute seizure at 4 days postinfection. The expanded 
traces corresponding to the boxes are shown below, illustrating EEG activity during 1) 
before seizure (baseline), 2) seizure, 3) postictal spiking, and 4) behavioral arrest 






Table 1.1 Salient features of the TMEV model of limbic epilepsy. 
 
 C57BL/6J mice infected intracortically with TMEV exhibit acute seizures 
during 3-10 days postinfection. 
 Mice survive the infection, clear the virus from the brain after about 2 weeks 
of infection, and later develop chronic seizures. Therefore, this is a ‘hit and 
run’ type of infection which results into development of limbic epilepsy. 
 Frequency of chronic unprovoked seizures during the epilepsy phase is low. 
 TMEV-infected mice have brain damage in the limbic structures. Loss of 
CA1 pyramidal neurons and tissue sclerosis in the hippocampus appear 
within a week of infection. 
 Excessive inflammatory response driven mainly by the cells of innate 
immunity (microglia, macrophages and astrocytes) contributes to the 
development of seizures. 
 Cytokines, primarily TNFα and IL-6, and complement protein C3 are 
strongly associated with the development of seizures. 
 TMEV-infected mice with acute seizures have a hyperexcitable neurocircuit 
in the forebrain and limbic structures and exhibit increased susceptibility to 
develop chronic seizures. 
 CA3 hippocampal neurons are hyperexcitable, however, the pattern of 
changes in excitatory and inhibitory functions differ between acute and 
chronic seizures, which suggests that the dynamic alterations in the 
hippocampal tri-partite circuit occur during epileptogenesis. 
 TMEV-infected mice with acute seizures show later behavioral and 






















Temporal lobe epilepsy (TLE) is the most common form of acquired epilepsy that 
can be caused by several inciting events including viral infections. However, one-third of 
TLE patients are pharmacoresistant to current antiepileptic drugs and therefore, there is 
an urgent need to develop antiepileptogenic therapies that prevent the development of the 
disease. Oxidative stress and redox alterations have recently been recognized as 
important etiological factors contributing to seizure-induced neuronal damage. The goal 
of this study was to determine if oxidative stress occurs in the TMEV (Theiler’s murine 
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encephalomyelitis virus) model of temporal lobe epilepsy (TLE). C57BL/6J mice were 
injected with TMEV or with saline intracortically and observed for acute seizures. At 
various time points after TMEV injection, hippocampi were analyzed for levels of 
reduced glutathione (GSH), oxidized glutathione (GSSG) and 3-nitrotyrosine (3NT). 
Mice infected with TMEV displayed behavioral seizures between 3 and 7 days 
postinfection (dpi). The intensity of seizures increased over time with most of the 
seizures being a stage 4 or 5 on the Racine scale at 6 dpi. Mice exhibiting at least one 
seizure during the observation period were utilized for the biochemical analyses. The 
levels of GSH were significantly depleted in TMEV-infected mice at 3, 4 and 14 dpi. 
with a concomitant increase in GSSG levels as well as an impairment of the redox status. 
Additionally, there was a substantial increase in 3NT levels in TMEV-infected mice at 
these time points. These redox changes correlated with the occurrence of acute seizures in 
this model. Interestingly, we did not see changes in any of the indices in the cerebellum 
of TMEV-infected mice at 3 dpi indicating that these alterations are localized to the 
hippocampus and perhaps other limbic regions. This is the first study to demonstrate the 
occurrence of oxidative stress in the TMEV model of infection-induced TLE. The redox 
alterations were observed at time points coinciding with the appearance of acute 
behavioral seizures suggesting that these changes might be a consequence of seizure 
activity. Our results support the hypothesis that redox changes correlate with seizure 
activity in acquired epilepsies, regardless of the inciting insults, and suggest oxidative 










Temporal lobe epilepsy or TLE, the most common form of acquired epilepsy is 
initiated by a variety of insults including traumatic brain injury, stroke, status epilepticus 
and infections, which can cause early seizures, and following a latent period, lead to the 
development of spontaneous seizures or epilepsy. The cascade of biochemical, molecular 
and structural alterations following a precipitating injury and culminating in the 
development of epilepsy, that is, epileptogenesis, is thought to involve processes such as 
neuronal loss, gliosis, axonal sprouting, neurogenesis and inﬂammation (Dudek and 
Staley, 2011; Sharma et al., 2007). A recent study indicates that patients that exhibit 
seizures during viral encephalitis are 22 times more likely to develop epilepsy than the 
control population (Misra et al., 2008). Thus, patients with encephalitis are at high risk 
for developing epilepsy. A novel mouse model of infection-induced TLE which 
recapitulates clinical observations has been recently developed which offers a unique 
opportunity to study the molecular mechanism(s) underlying epileptogenesis and to 
identify novel therapeutic strategies (Libbey et al., 2008). Theiler's murine 
encephalomyelitis virus (TMEV)-infected C57BL/6J mice show acute behavioral 
seizures between 3 and 7 days postinfection (dpi), exhibit neurodegeneration, and glial 
activation in the hippocampus. A signiﬁcant proportion of mice surviving the infection 
develop epilepsy after a latent period (Kirkman et al., 2010; Stewart et al., 2010a, b). In 
addition, the brains of TMEV-infected mice show increased expression of mRNA for 
proinﬂammatory cytokines, including tumor necrosis factor-α (TNFα) and interleukin-6 
(IL-6), during the acute seizure period (Kirkman et al., 2010). Given that TNFα receptor 




acute TMEV infection period, inﬂammation seems to play an important role in the 
induction of seizures in this animal model (Kirkman et al., 2010).  
Oxidative stress is an important mechanism known to occur following brain 
injuries, sufﬁcient to cause epilepsy (Liang et al., 2000). Endogenous antioxidants can 
overcome normal production of reactive oxygen and nitrogen species (ROS and RNS). 
However, their excessive production can overwhelm the natural antioxidant defenses and 
shift the redox state to a more oxidized environment which can lead to oxidative damage 
of various cellular targets. In fact, both mitochondrial and extracellular ROS play a role 
in mediating seizure-induced neuronal death (Liang et al., 2000; Patel et al., 2005). 
Additionally, oxidative stress has been shown to occur throughout epilepsy development 
in chemoconvulsant models of TLE (Liang and Patel, 2006; Patel, 2004; Waldbaum and 
Patel, 2010). Whether oxidative stress is a common mechanism underlying diverse 
epileptogenic injuries is unclear. We hypothesized that oxidative stress occurs in the 
Theiler's virus infection model of TLE for the following reasons. (1) Viral infections 
often cause increased formation of ROS and RNS either due to direct effects of the virus 
on the cells or as a consequence of host inﬂammatory responses to the infections 
(Schwarz, 1996; Valyi-Nagy et al., 2000). In response to viral infections, increased levels 
of cytokines, chemokines and other inﬂammatory mediators can directly damage 
mitochondria, resulting in oxidative stress. Herpes simplex virus (HSV) and Japanese 
encephalitis virus (JEV) are among the most common viruses which cause encephalitis 
and are both associated with acute seizures in patients (Theodore, 2014). Acute and 
chronic HSV-1 infection in mice results in inﬂammation and oxidative damage to the 




infection has also been shown to stimulate the formation of oxidative stress in rat cultured 
cortical glial cells and in an acute JEV rat model (Liao et al., 2002; Srivastava et al., 
2009). (2) Oxidative stress and mitochondrial dysfunction have the potential to lower 
seizure threshold by a variety of mechanisms including impaired ATP production 
(Jamme et al., 1995) and altered expression of transporters and enzymes crucial in the 
homeostasis of synaptic levels of neurotransmitter and intracellular calcium levels, thus 
tilting the balance of synaptic neurotransmission towards hyperexcitation (Waldbaum and 
Patel, 2010). Oxidative stress can further damage neurons by directly inducing apoptosis 
or necrosis and such aberrant neuronal loss can facilitate seizure generation (Kannan and 
Jain, 2000). Therefore, both inﬂammation and oxidative stress following viral infection 
may contribute to the development of acute seizures in the TMEV model. 
While inﬂammation has been well documented in the TMEV model of infection-
induced epilepsy, it is currently unknown if oxidative stress is observed during the acute 
seizure stage in TMEV infected mice. Therefore, the goal of the present study was to 
investigate the time course of oxidative stress in the TMEV-infection mouse model of 
TLE. We report here that TMEV-infected animals have a signiﬁcant depletion of reduced 
glutathione (GSH), an increase in oxidized glutathione (GSSG) levels, as well as an 
increase in 3-nitrotyrosine/tyrosine (3NT/Tyr) ratio. This data suggests that oxidative 
stress occurs in the TMEV model of CNS infection-induced epilepsy coincident with 














Male C57BL/6J mice aged between 4 and 5 weeks old were purchased from 
Jackson Laboratory (Bar Harbor, ME, USA). After arrival, mice were allowed to 
acclimatize for 3 days prior to the experiment. Mice were provided food and water ad 
libitum and kept in a facility providing 12 h of light and lark cycle starting at 6:00 AM. 
All the procedures performed were in accordance with the guidelines provided and 
approved by the Institutional Animal Care and Use Committee of the University of Utah. 
 
 
Treatment of mice and seizure monitoring 
 
Mice were anesthetized briefly using a mixture of isoflurane and compressed air. 
Mice were then injected with 20 µl of either phosphate-buffered saline (PBS, n = 30) or 
3x105 PFU (plaque forming units) of Daniels strain of TMEV (n = 50) intracortically to a 
depth of 2 mm in the temporal region of the right hemisphere (posterior and medial of the 
right eye). Mice were agitated by briefly shaking their cages and monitored for 
behavioral seizures for 1 h, twice a day and a minimum of 2 h apart from 8:00 AM to 
5:00 PM, until 10 dpi as previously described (Libbey et al., 2008). The intensity of the 
seizure activity was graded using the Racine scale as follows: stage 1, mouth and facial 
movements; stage 2, head nodding; stage 3, forelimb clonus; stage 4, rearing; and stage 5, 
rearing and falling (Racine, 1972). Mice were sacrificed at 8 h postinfection, and 1, 2, 3, 
4, and 14 dpi. For 3, 4, and 14 dpi, only TMEV-infected mice that had acute behavioral 
seizures were used, while nonseized mice from the TMEV group were excluded from the 




microdissected and collected separately. Cerebellum was also collected. All the tissue 
samples were flash-frozen using 2-methylbutane chilled on dry ice and stored at -80 ºC. 
The samples were shipped overnight on dry ice to the laboratory of Dr. Manisha Patel at 
the University of Colorado, Aurora, CO for the analysis.  
 
 
HPLC determination of GSH and GSSG 
 
Reduced and oxidized forms of GSH were measured by HPLC with 
electrochemical detection (HPLC-EC) following minor modifications to previously 
described methods (Lakritz et al., 1997; Liang and Patel, 2006). GSH and GSSG were 
detected using a CoulArray system (Model 5600, ESA) on two coulometric array cell 
modules, each containing eight electrochemical sensors attached in series. 
Electrochemical detector potentials were 150/300/450/570/690/800/850 mV. Frozen 
hippocampi obtained from Dr. Karen Wilcox’s laboratory were sonicated with 0.1 N 
perchloric acid (HClO4) immediately before thawing in a 1:10 weight by volume ratio. 
The homogenates were centrifuged at 13,000 x g for 10 min at 4 ºC. Aliquots of the 
supernatant (20 µL) were injected into the HPLC and separated on a 5 µM, 250 x 4.6-mm 
C-18 ODS-80Tm column (Tosoh Bioscience, Japan). The mobile phase was comprised of 
100 mM sodium phosphate, 1% methanol, pH 2.7 and a flow rate of 0.6 ml/min was 
maintained. Control values were normalized to one hundred percent and data is 










HPLC determination of 3-nitrotyrosine 
 
3-Nitroyrosine (3NT) and tyrosine levels were measured using a HPLC method 
similar to GSH and GSSG measurements and as previously described (Ryan et al., 2014). 
Frozen hippocampi samples were processed in the same way as described above and 20 
µl of the supernatant was injected into an ESA 5600 CoulArray HPLC (Chelmsford, 






GraphPad Prism 6 was used for all statistical analyses performed. Group 
differences were determined by analysis of variance (ANOVA) with Sidak’s multiple 





Acute behavioral seizures in TMEV-infected mice  
 
Behavioral seizures occur between 3 and 7 dpi in the TMEV model (Stewart et 
al., 2010a). Accordingly, seizures were not observed in animals sacrificed prior to day 3. 
As it was not possible to predict which animals would have gone on to develop seizures, 
the number of animals was increased (n = 8 per group) for the TMEV samples that were 
obtained at 8 h postinfection and at 1 and 2 dpi. The remaining animals (n = 26) were 
then assessed for seizure activity and 81% of those animals were observed to have had at 
least one seizure prior to sacrifice. However, on any given observation day, 




described, seizure severity increased over the course of the observation period, with the 
majority of seizures observed being either a stage 4 or 5 seizure by 6 dpi (Figure 2.1b and 
2.1c). Only those animals that exhibited at least one seizure during the observation 
periods were used for harvesting tissue for the remaining time points (3, 4, and 14 dpi; n 
= 5 per group).  
 
 
Impaired glutathione redox status in TMEV model 
 
To determine if oxidative stress occurs in TMEV infected mice, we measured the 
tissue redox status in the ipsi- and contralateral hippocampus of PBS- and TMEV-
injected mice. GSH is the most abundant nonprotein thiol as well as an extremely 
important nonenzymatic antioxidant in the body. The ratio of GSH to its oxidized form 
GSSG, a disulfide redox partner, is an excellent indicator of the overall tissue redox 
status and can be measured by HPLC analysis (Liang and Patel, 2006; Schafer and 
Buettner, 2001). A higher GSH/GSSG ratio indicates a reduced environment whereas a 
decrease in this ratio denotes a relatively oxidized tissue environment. Decreased 
GSH/GSSG correlates with structural damage to cellular membranes, DNA damage, 
posttranslational modifications to proteins and inactivation of essential enzymes, which 
can all affect neuronal excitability (Andersen, 2004; Waldbaum and Patel, 2010). Whole 
hippocampal (ipsilateral) GSH (Figure 2.2a) decreased significantly in TMEV-infected 
mice at 72 h (mean ± SEM = 74.712 ± 3.6%), 96 h (73.494 ± 4.236%), and 14 days 
(83.91 ± 5.010%) postinfection with a concomitant increase in GSSG (Figure 2.2b) levels 
(203.422 ± 45.697%, 238.291 ± 14.27%, 231.849 ± 41.642% for 72 h, 96 h and 14 days, 




2.2c) was also significantly decreased at these time points. The contralateral hippocampi 
displayed similar levels as PBS injected mice. This correlates with the onset of acute 
behavioral seizures indicating that tissue redox status is decreased as a consequence of 
either seizure activity and/or inflammation in the TMEV model, which is consistent with 
previous findings in the lithium-pilocarpine and kainate chemoconvulsant models of TLE 
(Jarrett et al., 2008; Ryan et al., 2014; Waldbaum et al., 2010). 
 
 
Increased 3-nitrotyrosine levels in TMEV-infected mice 
 
3-Nitrotyrosine (3NT) is a marker for protein nitration, a posttranslational 
modification that can lead to protein dysfunction or turnover. A major source of 3NT is 
peroxynitrite (ONOO−), produced from the reaction between nitric oxide (NO) and 
superoxide (O2•−), two highly reactive free radical species. ONOO−
 attacks tyrosine 
residues of proteins specifically, to form 3NT (Sawa et al., 2000). The levels of 3NT and 
free tyrosine (Tyr) can be measured utilizing HPLC and a higher ratio of 3NT/Tyr is an 
indicator of oxidative and/or nitrosative stress in tissues. The ratio of 3NT/Tyr in the 
ipsilateral hippocampus was significantly elevated at 72 h, 96 h, and 14 days (means ± 
SEM of 3NT/Tyr x 1000 = 4.707 ± 0.566, 6.297 ± 0.801 and 4.44 ± 0.428, respectively) 
postinfection compared to their respective controls (Figure 2.3). Thus, this data 
demonstrate that acute seizure activity in mice infected with TMEV leads to an increase 








No change in oxidative stress indices in the 
 
cerebellum of TMEV-infected mice 
 
In order to determine if the alterations in oxidative and nitrosative stress are 
localized to any regions other than the hippocampus, we measured GSH, GSSG, and 3NT 
levels in the cerebellum of mice injected with TMEV and PBS at 3 dpi. There were no 
significant differences between PBS- and TMEV-infected mice in any of the oxidative 
stress indices measured (Figure 2.4) indicating that the redox changes are specific to the 





This study demonstrates for the first time, that acute seizures resulting from 
TMEV infection in mice leads to the occurrence of oxidative and nitrosative stress which 
along with inflammation, might be contributing to the development of epilepsy in this 
model. We have shown that (1) the glutathione redox status is significantly impaired and 
(2) 3-nitrotyrosine levels are significantly increased following acute seizures in the 
TMEV model of infection-induced epilepsy. These results are consistent with previous 
findings in the lithium-pilocarpine and kainate chemoconvulsant models of TLE and 
verify that ROS and RNS are elevated as a consequence of acute seizure activity 
regardless of the initiating injury and point to the fact that oxidation- and nitration-
induced posttranslation modifications might play an important role in epileptogenesis and 
associated pathologies.  
The TMEV mouse model of epilepsy was generated by the injection of the 




develop short-term encephalitic seizures within 3 to 7 dpi. Previously published research 
has demonstrated similar results as well as confirmed the development of chronic, 
spontaneous seizures starting at around 2 months postinfection by video-EEG recordings 
(Stewart et al., 2010a). The development of epilepsy was also associated with 
hippocampal sclerosis and astrogliosis in these animals, hallmarks of mesial TLE 
(Stewart et al., 2010a). Viral infection-induced models of epilepsy, such as the West Nile 
(WNV), measles, and herpes simplex viruses (HSV), have been difficult to address 
experimentally due to a variety of reasons including fatality from acute viral encephalitis, 
or lack of spontaneous seizures or the persistence of the virus throughout the animal’s 
life. The TMEV-infected mice not only survive the infection and develop spontaneous 
seizures, but also clear the virus by 14 dpi (Kirkman et al., 2010). Therefore, TMEV-
infected C57BL/6J mice present us with a potential model to study the mechanisms 
underlying the development of acute seizures, epileptogenesis, and consequent epilepsy 
following a viral infection of the CNS (Stewart et al., 2010a, b). In addition, this model 
may be useful in identifying novel disease-modifying therapies for the prevention of 
epilepsy.  
One distinguishing feature of the TMEV model is the occurrence of inflammatory 
changes in the brains of the infected mice which is believed to contribute to the 
development of acute seizures. Specifically, activation of the innate but not the adaptive 
immune system in response to the infection was implicated which included substantial 
increases in TNFα and IL-6 mRNA levels, along with microglial infiltration and 
astrogliosis (Kirkman et al., 2010). Viral infections of the CNS have also been associated 




component of acute encephalitis caused by HSV-1, HIV, and measles virus. Increased 
ROS and RNS production can be a direct effect of the virus and a result of the 
inflammatory response of the host (Valyi-Nagy and Dermody, 2005). Oxidative stress 
and tissue redox status in turn can stimulate the production of proinflammatory cytokines 
(Iyer et al., 2009). Here, we show that ROS and RNS are increased acutely, as measured 
by the tissue GSH redox status and 3NT/Tyr ratios, resulting from seizure activity that 
arises due to induction of innate immune responses, highlighting the relationship between 
oxidative stress and inflammation in this model. 
GSH is an important antioxidant responsible for scavenging harmful reactive 
species and maintaining a reduced environment in tissues. GSH depletion occurs in 
several disease states including TLE and the ratio of GSH/GSSG serves as a very 
important indicator of the tissue redox status and oxidative stress. GSH depletion has 
been implicated in aging as well as other acute and chronic neuronal disorders (Liu et al., 
2004; Sims et al., 2004). Here, we show that the GSH levels are significantly depleted at 
3, 4, and 14 dpi concomitant with increases in GSSG levels rendering the overall tissue 
redox status more oxidized. This is consistent with our previous findings of ROS 
production and altered redox state in two different chemoconvulsant models of TLE, the 
kainate and lithium-pilocarpine models, where status-epilepticus is the initiating cause of 
redox changes (Liang and Patel, 2006; Ryan et al., 2014; Waldbaum et al., 2010). The 
decrease in the GSH redox status persisted at 14 dpi which represents the latent phase in 
this model during which the mice do not have any behavioral seizures. Seizures in 
TMEV- infected mice reemerge spontaneously 8 weeks postinfection (Stewart et al., 




could have a potential role in epilepsy development. However, mechanistic studies are 
needed to deﬁnitively conclude whether these changes in oxidative stress are causal to 
seizure progression. Nevertheless, our results conﬁrm that decreased GSH redox status is 
a common phenomenon occurring in animal models of TLE despite the type of 
precipitating injury, indicating that this could be an important mechanism contributing to 
spontaneous seizures in TLE. 
A variety of mechanisms could lead to the decreased GSH/GSSG ratio in this 
model. First, it has been previously shown that chemoconvulsant-induced status 
epilepticus leads to an increase in steady-state mitochondrial O2•−
 levels resulting in the 
production of hydrogen peroxide (H2O2) which can diffuse out of the mitochondria into 
the cellular space and deplete cellular GSH pools (Liang et al., 2000). Second, 
posttranslational inactivation of the iron-sulfur (Fe-S)-containing TCA cycle enzyme, 
aconitase, mediated by O2•−, which can also pose an additional oxidative burden by 
producing equimolar amounts of H2O2 per mole of O2•−. It is noteworthy here that the 
production of O2•−
 precedes neuronal death in the kainate model and the latter can be 
prevented by treatment with a broad-spectrum antioxidant, as well as by overexpressing 
mitochondrial superoxide dismutase or SOD2 in mice (Liang et al., 2000). Stewart et al., 
have previously published that TMEV-infected mice have increased neuronal death in the 
hippocampus at 4–6 dpi (Stewart et al., 2010a). Thus, altered GSH redox state which is 
observed starting 3 dpi could be a major factor contributing to the brain pathology of 
TMEV-infected mice and the development of epileptic seizures. Therefore, future studies 
investigating the ability of antioxidants to prevent cell death in this model is warranted. 




product resulting from nitration of tyrosine residues in proteins by mainly peroxynitrite 
(ONOO−). ONOO− is the product of the reaction between O2•− and NO, both of which 
can be generated as a consequence of seizure activity as shown previously in the kainate 
model (Liang et al., 2000; Ryan et al., 2014). Interestingly, inflammatory cytokines can 
also lead to the formation of extracellular O2•−
 and NO by activation of the NADPH 
oxidases (Nox) and inducible nitric oxide synthase (iNOS), respectively (Dikalov, 2011). 
Furthermore, our previous work has also illustrated activation of Nox2 in the kainate 
model (Patel et al., 2005). Therefore, in the TMEV-infected mice, 3NT formation could 
be a consequence of NO production from acute seizures or it could be a direct 
consequence of the release of proinflammatory molecules. The increase in 3NT levels 
presents with a unique hypothesis where ROS/RNS-induced posttranslational 
modifications (PTMs) underlie the damaging subcellular events that promote 
epileptogenesis. PTMs associated with altered redox status are associated with cysteine 
(Cys) residues with low pKa or thiol groups in proteins (Giustarini et al., 2004; Jones, 
2008). Such modifications can either exert a protection from further oxidation or if the 
Cys residue is functionally important, PTMs can disrupt the protein’s biological function. 
As an example, Ryan et al., have recently demonstrated that carbonylation of complex I 
of the electron transport chain (ETC) is increased in the acute and chronic phases of 
epileptogenesis in the kainate model, which correlated with decreases in complex I 
activity. Mass spectrometric analysis of this PTM identified the site as Arg76 within the 
75 kDa subunit of the complex (Ryan et al., 2012). Moreover, 3NT was shown to 
accumulate in the hippocampal neurons and not astrocytes in the kainate model 




this evidence brings forth the notion that PTMs resulting from seizure-induced ROS or 
RNS production can mediate neuronal death and the development of spontaneous 
seizures in the TMEV model. Further investigation into the role of ROS/RNS in the 
TMEV model can be warranted by determining the effect of an antioxidant on cell death 
and epileptic seizures in this model.  
To summarize, we have demonstrated that acute seizures, arising from 
inflammation in the TMEV model of infection-induced epilepsy, lead to the production 
of ROS and RNS. In our studies we have reported a decrease in the GSH redox status as 
well as an increase in 3NT levels indicative of oxidative and nitrosative damage 
respectively. These results agree with previous findings illustrating the occurrence of 
oxidative and nitrosative stress in SE models of TLE, suggesting that these biochemical 
changes are common phenomena in animal models of TLE, irrespective of the initiating 
injury. Furthermore, our results point to the role of ROS- and RNS-mediated PTMs as 
well as highlight the interaction between redox and inflammatory processes in the TMEV 
model, which could be the mechanisms underlying the pathology observed in this model. 
Finally, this study underscores the relationship between redox mechanisms and seizure 
activity in the TMEV model and lays the groundwork for further investigation and 
development of therapeutic strategies targeting redox processes for the treatment of 
acquired epilepsies. 
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Figure 2.1 Acute behavioral seizures in TMEV-infected mice. Mice infected with TMEV 
show acute behavioral seizures between 3 and 7 days postinfection. (a) While 81% of the 
TMEV-infected animals exhibited at least one seizure during the observation period, only 
approximately 50% of the mice were observed to have behavioral seizures on any given 
day between 3 and 7 dpi. (b) Distribution of mice which experienced acute seizures 
following TMEV infection based on the seizure intensity graded according to the Racine 
scale. For a mouse which had more than one seizure on any given day, the highest scale 
of seizure intensity was considered for the plot. Decreasing numbers of animals over time 
reflect the fact that animals were being sacrificed at different time points throughout the 
study. (c) Consistent with previous studies (Stewart et al., 2010b; Umpierre et al., 2014), 
the total numbers of seizures based on the Racine scale on each day during seizure 
monitoring show that seizure intensity increases over the course of observation period. 








Figure 2.2 Impaired GSH redox status in TMEV-infected mice. Hippocampal GSH redox 
status is impaired in mice infected with TMEV. Levels of GSH (a), GSSG (b) and the 
ratio of GSH/GSSG (c) were measured in the mouse ipsilateral hippocampus using HPLC 
with electrochemical detection. Mice were injected with PBS or TMEV and sacrificed at 
indicated times (n≥5 mice per group). Values were normalized to percent of control 
values and presented as values ± SEM. The dotted line indicates 100%. Statistics: 
*=p<0.05, **=p<0.01, ***=p<0.001 and ****=p<0.0001 versus respective PBS controls; 








Figure 2.3 Increased levels of 3NT in TMEV-infected mice. Hippocampal 3NT levels 
were elevated in TMEV-infected mice. Mice were injected with PBS or TMEV and 3NT 
levels were measured at the indicated times with HPLC-EC (n = 4-5 mice per group). 
Data are represented as the ratio of 3-nitrotyrosine to tyrosine (3NT/Tyrosine x 1000) as 
values ± SEM. Statistics: *=p<0.05 and ****=p<0.0001 versus respective PBS controls; 








Figure 2.4 No oxidative stress in cerebellum of TMEV mice at 3 dpi. Mice were injected 
with PBS or TMEV and GSH, GSSG, 3NT and Tyr levels were measured at 3dpi with 
HPLC-EC (n = 5 mice per group). GSH and GSSG levels are presented as nmols/g tissue 
and as the ratio of GSH/GSSG. 3NT levels are presented as the ratio of 3NT to tyrosine 
(3NT/Tyr x 1000). All data is represented as values ± SEM. Statistical analysis used here 












HIPPOCAMPAL TNFα SIGNALING CONTRIBUTES TO 
HYPEREXCITABILITY IN AN INFECTION- 






Encephalitis as a consequence of viral infections of the CNS is often associated 
with the occurrence of acute seizures and a dramatically increased probability of the 
subsequent development of acquired epilepsy (Vezzani et al., 2016). Indeed, a 
retrospective epidemiological study found an overall 22-fold increase in the risk for 
developing epilepsy following viral encephalitis if patients present with acute seizures 
(Misra et al., 2008). CNS infection can cause intense inflammatory responses and 
parenchymal damage in the brain contributing to acute seizures which, in turn, can 
exacerbate inflammatory conditions, ensuring further CNS damage and the development 
of recurring chronic seizures (Vezzani et al., 2011; Vezzani et al., 2016). Therefore, 
investigating the role of inflammation as a consequence of CNS infection could provide 
valuable insight for the development of next generation disease-modifying therapies for 
the prevention of epilepsy. 




acute seizures between 3 and 8 days postinfection (dpi), exhibit pathological and 
physiological changes such as astrogliosis, microgliosis, neuronal loss in CA1, and 
increased excitatory synaptic transmission in CA3 pyramidal neurons in the 
hippocampus. Importantly, the mice survive the infection, clear the virus from the brain, 
present with cognitive impairment and anxiety-like symptoms and develop chronic 
spontaneous seizures after a latent period (Broer et al., 2016; Kirkman et al., 2010; 
Libbey et al., 2008; Loewen et al., 2016; Smeal et al., 2012; Stewart et al., 2010a; 
Umpierre et al., 2014). Thus, TMEV-infected mice recapitulate many clinical 
observations from patients suffering from infection-induced temporal lobe epilepsy 
(TLE) and offer a unique opportunity to study the molecular mechanism(s) underlying 
the process of infection-induced epileptogenesis.  
TMEV infection results in a dramatic increase in the expression of cytokines, 
chemokines, oxidative stress markers, and infiltration of macrophages in the first week of 
infection which may contribute to the initiation and/or propagation of seizures during the 
acute infection period in this model (Bhuyan et al., 2015; Cusick et al., 2013; Kirkman et 
al., 2010). The level of tumor necrosis factor-α (TNFα) mRNA in the whole brain of 
TMEV-infected mice exhibiting acute seizures was increased by 128-fold at 6 dpi 
compared to control mice (Kirkman et al., 2010). Further, only 10% of TNFα receptor 1 
knock-out (TNFR1 KO) mice developed acute behavioral seizures compared to 52% of 
wild-type (WT) control mice, which implies a significant role of TNFR1-mediated effects 
of TNFα in seizure development in this model (Kirkman et al., 2010). 
TNFα signaling through the TNFR1 pathway has been shown to contribute to the 




α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) under both 
physiological and pathogenic conditions (Beattie et al., 2010). TNFα increases the 
expression of GluR1-containing and GluR2-lacking AMPARs on the surface of cultured 
hippocampal neurons and in pyramidal cells in acute rat hippocampal slices (Beattie et 
al., 2002; Stellwagen et al., 2005; Stellwagen and Malenka, 2006). Whole cell patch-
clamp recordings from CA1 pyramidal neurons in acute hippocampal slices pretreated 
with TNFα show significant increases in average amplitudes of miniature excitatory 
postsynaptic currents (mEPSCs) (Stellwagen et al., 2005). This suggests that TNFα may 
contribute to hyperexcitability by augmenting excitatory synaptic strength by increased 
trafficking of AMPARs subunits to postsynaptic membranes (Stellwagen et al., 2005; 
Stellwagen and Malenka, 2006). The effects of TNFα on regulating excitatory synaptic 
strength have also been described in rodent models of spinal injury (Ferguson et al., 
2008), pain (Choi et al., 2010), and glaucoma (Cueva Vargas et al., 2015).  
The present experiments were performed to evaluate the role of hippocampal 
TNFα signaling in seizure generation during the acute period following TMEV infection. 
We found a significant increase in expression of both hippocampal mRNA and protein 
levels of TNFα following TMEV infection that was coincident with focal seizure activity. 
In addition, a significant increase in the TNFR1:TNFR2 ratio in hippocampus suggests 
that signaling through the TNFR1 pathway predominates during the acute infection 
period. Consistent with increased TNFR1 signaling, increases in hippocampal cell surface 
AMPA receptor expression was also observed during the acute period. While treatment 
with XPro1595, a mutant form of human soluble TNFα (sTNFα) that acts as a dominant-




infection period, several lines of transgenic animals deficient in either TNFα or its 
receptors were found to have robust changes in seizure incidence and severity following 
TMEV infection. Taken together the present results suggest that increases in TNFα 
signaling, likely through the TNFR1 pathway, contributes to hyperexcitability and the 
increased probability of seizures in the hippocampus following TMEV infection. 
Therefore, this pathway may provide a novel target for antiseizure and disease modifying 







C57BL/6J mice (WT (#006460), TNFR2-/- (#002620), TNFR1-/-TNFR2-/- 
(#003243), and TNFα-/- (#005540)) aged between 4-6 weeks were purchased from 
Jackson Laboratory. TNFR2-/-, TNFR1-/-TNFR2-/-, and TNFα-/- mice were bred at our 
vivarium. All the KO mice were on C57BL/6J background and the deletion of the target 
protein was confirmed by PCR. All the experiments were carried out in male mice unless 
otherwise specified. After arrival, mice were allowed to acclimatize for at least 3 days 
prior to the experiment. Mice were provided food and water ad libitum and kept in a 
facility providing 12 h of light and lark cycle starting at 6:00 AM. All the procedures 
performed were in accordance with the guidelines provided and approved by the 










Method of TMEV infection and seizure monitoring 
 
Mice are briefly anesthetized with 3% isoflurane and injected with 20 µl of either 
phosphate-buffered saline (PBS) or DA-TMEV solution intracortically in the right 
hemisphere by inserting the needle at a 90° angle to the skull. The injection region is 
located slightly medial to the equidistant point on the imaginary line connecting the eye 
and the ear. A sterilized syringe containing a plastic jacket on the needle exposing 2.5 
mm of needle is used for infection to restrict the injection site to the somatosensory 
cortex without damaging the hippocampus. TMEV titer injected per mouse ranged from 
2x104 to 3x105 PFU (plaque forming units) depending on the experiment.  
Mice were briefly agitated by shaking their cages and monitored for behavioral 
seizures twice daily in the morning and afternoon separated by a minimum of 2 h until 10 
dpi. Seizure intensity was graded using modified Racine scale as follows: stage 1, mouth 
and facial movements; stage 2, head nodding; stage 3, forelimb clonus; stage 4, forelimb 
clonus, rearing; and stage 5, forelimb clonus, rearing, and falling; stage 6, intense 
running, jumping, repeated falling, and severe clonus. Seizure frequency was reported as 
an average number of seizures during the entire acute seizure period, whereas seizure 
severity/intensity was represented as an average cumulative seizure burden at each dpi 
during acute seizure period. Cumulative seizure burden at each dpi for a mouse was 
calculated by summing all of its seizure scores up to that dpi.  
 
 
Tissue collection for mRNA and protein analysis 
 
TMEV-infected mice that had acute behavioral seizures were used for all the 




depending on the experiment. The ipsilateral and contralateral hippocampi were rapidly 
isolated and collected separately. All the tissue samples were flash frozen using 2-
methylbutane chilled on dry ice and stored at -80 ºC until further processing.  
 
 
Multiplex cytokine array 
 
The protein levels of an array of cytokines were measured in mouse ipsilateral 
hippocampal lysates using a multiplex kit (V-PLEX™, K15048D) from Mesoscale 
Discovery according to manufacturer’s instructions. Briefly, ipsilateral hippocampi were 
homogenized in MSD Tris lysis buffer in a 1:10 weight by volume ratio, centrifuged and 
the supernatant collected. Protein concentration was determined using the Bradford assay 
and 250 µg of protein was loaded per well to measure cytokines. The levels of analytes 
were determined by measuring the intensity of emitted light at 620 nm using a Sector 
Imager 2400.  
 
 
Gel electrophoresis and western blot  
 
Protein expressions of TNFRs were quantified by western blot analysis. The 
ipsilateral hippocampi were homogenized in 10 µl of lysis buffer (25 mM Tris-HCl, 150 
mM NaCl, 1 mM EDTA, 1% Igepal CA-630, 5% glycerol, protease inhibitors (cocktail 
tablet, Roche), and 1 mM sodium orthovanadate) per mg of tissue and the supernatant 
was collected after centrifugation. Total protein concentration was measured by BCA 
protein assay (Pierce) and 10 µg of total protein was electrophoresed using 
polyacrylamide gel (4-12% Bis-Tris gel, NuPAGE™, Invitrogen) under denaturing 




chemiluminescence (NEL105001EA, PerkinElmer) using rabbit polyclonal antibodies 
against TNFR1 (#ab64006, 1:25000, Abcam), TNFR2 (#3727, 1:1000, Cell Signaling 
Technologies) and actin (#A2103, 1:250000, Sigma) followed by HRP-conjugated 
secondary antibody (#65-6120, 1:3000, Invitrogen). Densitometric analysis of protein 
levels was performed using ImageJ software (National Institute of Health, NIH). 
 
 
Quantitative reverse transcription polymerase  
 
chain reaction (RT-qPCR) 
 
Total RNA was isolated from the hippocampi samples by Trizol/chloroform 
extraction and purified to remove genomic DNA contamination by DNase treatment 
followed by a spin column-based method (RNeasy Mini Kit, Qiagen) according to 
manufacturer’s instructions. Quality and quantity of RNA were validated by 
spectrophotometry and acrylamide gel electrophoresis which showed intense discrete 
ribosomal RNA bands devoid of genomic DNA. cDNA was synthesized from RNA using 
random primers (SuperScript® VILO Master Mix, Invitrogen) and amplified by qPCR 
(LightCycler®480, Roche) using 1 µg cDNA with Luminaris Color HiGreen qPCR 
Master Mix (Thermo Fisher Scientific) and 0.3 µM primers for TNFR1 (Forward (F), 5’-
AGAGAAAGTGAGTGCGTCCC-3’; Reverse (R), 5’-AGCCTTCTCCTCTTTGAC-
AGG-3’), TNFR2 (F, 5’-AGCTGCAGTTCTTCCTGTACC-3’; R, 5’-GATGCTACA-
GATGCGGTGGG-3’), TNFα (F, 5’-CTGAACTTCGGGGTGATCGG-3’, R, 5’-GGC-
TTGTCACTCGAATTTTGAGA-3’, β-actin (F, 5’-AGATCAAGATCATTGCTCC-
TCC-3’, R, 5’-ACGCAGCTCAGTAACAGTCC-3’) and GAPDH (F, 5’-AGCTAC-




used a second derivative formula to calculate threshold cycle (CT). Primer efficiency for 
each analyte was determined using four dilutions of cDNA, and the primer efficiency was 
used to calculate ΔCT and ΔΔCT relative to the reference gene as well as PBS-treated 
control group. Primer specificity was confirmed by melt curves followed by agarose gel 
electrophoresis for the expected size product.  
 
 
Treatment of TMEV-infected mice with XPro1595  
 
TMEV-infected mice were treated with 10 or 100 mg/kg of XPro1595 
subcutaneously either every third day or daily. Vehicle contained 150 mM NaCl, 10 mM 
L-histidine, and 0.01% w/v Tween-20 in deionized water (pH 6.51). For 
intracerebroventricular (i.c.v.) administration of XPro1595, the guide cannula was 
surgically implanted into the left lateral ventricle using stereotaxic coordinates of -1.1 
mm lateral, -0.5 mm posterior, and -3.0 mm ventral from the bregma as described in 
detail previously (DeVos and Miller, 2013). Briefly, mice were anesthetized by 10 ml/kg 
i.p. injection of a mixture of ketamine and xylazine solution in sterile PBS (final 
concentration: ketamine – 10.4 mg/ml, Xylazine – 1.6 mg/ml) and the skull was exposed 
in a sterile surgical environment. Guide cannulas (C315GS-5/SP, 3 mm below pedestal, 
PlasticsOne) were inserted into the left lateral ventricle using a sharp beveled end of the 
cannula and glued to the skull. A dummy cannula (C315DCS-5/SPC, PlasticsOne) was 
placed in the guide cannula to prevent the exposure of the ventricle to the outside 
environment. Mice were allowed to recover from surgery for 12-15 days before initiating 
the experiment. Mice were immobilized during drug infusion by anesthetizing them using 




before the drug infusion in a laminar flow hood under aseptic conditions. An internal 
cannula (C315IS-5/SPC, PlasticsOne) connected to a 10 µl Hamilton® syringe via tubing 
was inserted into the guide cannula to infuse either XPro1585 or the vehicle solution. An 
infusion pump (PHD 2000 programmable, Harvard Apparatus) was used to infuse either 
5 µl of 40 mg/ml XPro1595 at 1 µl/min (0 and 2 dpi) or 2.5 µl of 80 mg/ml XPro1595 at 
0.5 µl/min (4 and 6 dpi). The internal cannula was kept in place for about 1 min after 
infusion and then slowly removed to avoid leakage. The dummy cannula was secured 
into the guide cannula immediately.  
 
 
Cell surface biotinylation assay  
 
Horizontal brain slices (350 µm) from control and TMEV-infected mice with 
seizures were prepared by vibratome at 5 dpi in ice-cold sucrose solution (concentrations 
in mM: 200 sucrose, 3 KCl, 26 NaHCO3, 1.4 NaH2PO4, 10 glucose, and 3 MgSO4 and 1 
CaCl2 added before use; 4°C) and collected in artificial cerebrospinal fluid (aCSF, 
concentrations in mM: 126 NaCl, 3 KCl, 26 NaHCO3, 1.4 NaH2PO4, 10 glucose, and 2 
MgSO4 and 2 CaCl2 added before use; pH, 7.33-7.35; osmolality, 297-303 mOsm/kg) at 
room temperature. Only brain slices ipsilateral to the injection were used for further 
processing. The slices were incubated in aCSF (31°C) for 45-50 min to recover from the 
surface damage inflicted during slicing. All the remaining steps were conducted at 4°C. 
The slices were washed with aCSF to remove dead surface cells and debris and incubated 
in 1 mg/ml solution of Sulfo-NHS-SS-biotin (Pierce) for 30 min to biotinylate cell 
surface proteins. The excess biotin solution was washed off using aCSF, quenched by 




hippocampal regions were dissected out quickly, collected in 250 µl lysis buffer (recipe 
same as described in western blot procedure), homogenized, centrifuged (14,000 x g, 15 
min, 4°C) and the supernatant was collected. All the solutions used for processing brains 
and brain slices were continuously oxygenated with the mixture of 95% oxygen and 5% 
carbon dioxide.  
Total protein (biotinylated surface proteins and nonbiotinylated intracellular 
proteins) concentrations in the supernatant were measured by a BCA protein assay 
(Pierce). To isolate biotinylated surface proteins (SP) from the total proteins (TP), 50 µg 
of TP was incubated with 25 µl of streptavidin beads (NeutrAvidin™, Thermo scientific) 
overnight at 4°C on a rotator. The appropriate ratio of beads to TP for each protein of 
interest was empirically measured by incubating a constant volume of beads with a range 
of TP in order to isolate the corresponding SP, as described in detail (Gabriel et al., 
2014). We chose a ratio of beads to TP of 1:2, which was found to isolate SP in a linear 
range. The mixture of beads and TP was centrifuged and the beads were washed with 
lysis buffer. The SP were eluted by incubating the beads in 20 µl of 2X SDS-PAGE 
reducing sample buffer containing 50 mM DTT in the final mixture (4X SDS-PAGE 
sample buffer: 106 mM Tris-HCl, 141 mM Tris-base, 0.51 mM EDTA, 2% SDS, 10% 
glycerol) for 30 min with continuous gentle mixing at room temperature. The supernatant 
containing SP was collected after centrifugation (17,000 x g, 2 min). The expression of 
GluA1 and GluA2 subunits of AMPARs were measured in both SP and TP fractions by 
SDS-PAGE and western blot (anti-GluA1 mAb #MAB2263 and anti-GluA2 mAb 
#MAB397, Millipore) as described above. The entire volume of supernatant containing 






Mice were sacrificed and their brains were removed between 3-7 dpi, and 350 µM 
horizontal brain slices were cut in ice-cold sucrose solution and incubated in aCSF 
solution for 1 h at room temperature. Miniature EPSCs were recorded from the dentate 
granule cells (DGCs) by whole-cell patch-clamp in aCSF solution containing 1 µM 
tetrodotoxin as described previously (Smeal et al., 2012). The internal recording solution 
contained (in mM): 129 potassium gluconate, 6 CsCl, 10 HEPES, 1 EGTA, 0.5 CaCl2, 10 
glucose, 2 ATP, 0.5 GTP, 5 QX314, 1 NaCl, and 5 tetraethylammonium chloride. The 
equilibrium potential for ionotropic glutamate receptors (iGluR ENa+/K+) was 4.66 mV at 
room temperature and mEPSCs were recorded by clamping the cell at -70 mV. Properties 
of the miniature currents analyzed included amplitude, interevent interval, frequency, rise 





Datasets involving continuous variables are represented by the average and the 
standard error of the mean (SEM), and the datasets with ordinal variables by frequency 
distribution. Experimental design involving two groups with one continuous dependent 
variable was analyzed by unpaired two-tailed t test, whereas design involving more than 
two groups with two categorical independent variables and one continuous dependent 
variable was analyzed by two-way ANOVA. Multiple comparisons were performed by 
Bonferroni posttest. Average cumulative seizure burden, which was calculated from a 
ranked dataset, was analyzed by Scheirer-Ray-Hare test which is an extension of the 




groups with binomial outcome were analyzed by Fisher’s exact test. “Survival” (% 
seizure free) curves and cumulative distributions were analyzed by log-rank test and 
Kolmogorov-Smirnov test, respectively. Densitometry of immunoblot images and the 
analysis of mEPSCs were conducted by Image J (NIH) and Mini Analysis Program 
(Version 6.0.7, Synaptosoft), respectively. Statistical calculations were conducted using 





Increased expression of TNFα and other cytokines in the  
 
hippocampus following TMEV infection 
 
Previous studies have demonstrated that TNFα mRNA levels increase 
dramatically by 128-fold in whole brain homogenates of TMEV-infected mice with acute 
behavioral seizures at 6 dpi compared to noninfected control mice (Kirkman et al., 2010). 
TMEV infection results in significant cell loss in the CA1 region, increased c-fos 
immunoreactivity in the hippocampus following TMEV-induced acute seizures, and 
increased excitability in the CA3 region of the hippocampus, a brain region often 
associated with seizure initiation in TLE (Smeal et al., 2012). Therefore, it is important to 
determine the role of hippocampal TNFα in TMEV-induced seizures. We measured the 
expression levels of TNFα mRNA and protein in the hippocampus of TMEV-infected 
mice and PBS-injected control mice. TMEV-infected mice exhibit acute behavioral and 
electrographic seizures between 3-8 dpi. Therefore, we measured the levels of TNFα at 1, 
5, and 14 dpi to compare the levels before, during, and after the acute seizure period. 




studies, as the presence of depth electrodes could influence the cytokine response. The 
mRNA level of TNFα in TMEV-infected mice was not significantly different at 1 dpi 
compared to control mice (n = 4) (Figure 3.1a). However, it dramatically increased by 
161-fold (n = 4, p<0.001) at 5 dpi during the peak of the acute seizure activity and it was 
still 88-fold higher at 14 dpi (n = 4, p<0.001) (Figure 3.1a). Similarly, immunoassay 
studies found no significant increase in the protein expression of TNFα in the 
hippocampus of TMEV-infected mice compared to control mice at 1 dpi, but TNFα was 
elevated 206-fold (p<0.001) and 35-fold (p<0.05) at 5 and 14 dpi, respectively (Figure 
3.1b, Table 3.1) (Control: n = 5 (all time points); TMEV: n = 8 (1 dpi), 6 (5 dpi), and 5 
(14 dpi)). The absolute average (± SEM) levels of TNFα were measured as follows: 4.89 
± 1.19 pg/ml (control) and 33.80 ± 3.09 pg/ml (TMEV) at 1 dpi; 0.54 ± 0.22 pg/ml 
(control) and 110.50 ± 7.96 pg/ml (TMEV) at 5 dpi; and 1.41 ± 0.65 pg/ml (control) and 
48.92 ± 10.02 pg/ml (TMEV) at 14 dpi. Additionally, protein levels of many other 
cytokines were also increased in the hippocampus in TMEV-infected mice with seizures 
at 5 dpi (Table 3.1), notably interferon-γ (IFNγ) which was 21,734-fold elevated 
compared to control mice. In addition, the antiinflammatory cytokine, interleukin-10 (IL-
10), was also increased by 47-fold, which suggests that negative immune feedback also 
occurs during acute TMEV infection to control excessive inflammation.  
 
 
Increased protein expression ratio of TNFR1:TNFR2  
 
in hippocampus during acute seizures 
 
The TNFα receptors, TNFR1 and TNFR2, mediate contrasting effects of TNFα in 




of TNFR1 and TNFR2 have been shown in the hippocampus in a rat model of limbic 
epilepsy (Weinberg et al., 2013). Therefore, we measured the expression of TNFR1 and 
TNFR2 in hippocampus following TMEV infection by western blot. Figure 3.1c shows a 
representative western blot image for TNFR1, TNFR2, and actin (gel loading control) 
from TMEV-infected mice at 1, 4, and 14 dpi along with PBS-treated control mice. 
Optical density (OD) analysis revealed a slight but significant reduction in the expression 
of TNFR1 in TMEV-infected mice at 4 dpi (OD: 0.97 ± 0.012 vs. 0.83 ± 0.01, n = 5-6, 
p<0.05) and 14 dpi (OD: 0.95 ± 0.03 vs. 0.75 ± 0.064, n = 5-6, p<0.01) after normalizing 
the data with actin levels (Figure 3.1d). However, the expression of TNFR2 protein levels 
were dramatically reduced at 4 dpi (OD: 0.90 ± 0.029 vs. 0.51 ± 0.038, n = 5-6, p<0.001) 
and 14 dpi (OD: 0.99 ± 0.049 vs. 0.42 ± 0.087, n = 5-6, p<0.001) (Figure 3.1d). The ratio 
of TNFR1:TNFR2, indicating the relative expressions of both TNFRs in the hippocampus 
during the acute infection period, was significantly elevated (1.08 ± 0.033 vs. 1.67 ± 
0139, p<0.05) at 4 dpi and was further increased at 14 dpi (0.97 ± 0.057 vs. 2.04 ± 0.255, 
p<0.001) (Figure 3.1d) which suggests that TNFα may mediate its downstream effects 
predominantly through TNFR1 in the hippocampus during the acute TMEV infection 
period.  
We also measured the mRNA levels of both TNFRs using qPCR. In contrast to 
TNFα, we found opposite changes in the levels of both TNFR1 and TNFR2 for mRNA 
and protein expression. The expression of TNFR1 mRNA was significantly elevated by 
2.59, 5.5, and 4.65-fold at 1, 5, and 14 dpi, respectively, (n = 4); whereas the protein 
levels were slightly reduced (Figure 3.1e). Similarly, mRNA expression of TNFR2 was 




reduced by 0.57- and 0.42-fold at 4 and 14 dpi (Figure 3.1f). These changes result in a 
progressive decrease in the relative mRNA expression ratios of TNFR1:TNFR2 and an 
increase in the relative protein expression ratios of TNFR1:TNFR2 in the hippocampus 
during acute TMEV infection (Figure 3.1g). This suggests that TNFR expression 
undergoes posttranslational regulation.  
 
 
Lack of seizure control following peripheral administration  
 
of XPro1595 on TMEV-induced acute seizures 
 
There is a significant increase in whole brain and hippocampal TNFα mRNA, an 
increase in protein expression of TNFα, and an increase in the ratio of TNFR1:TNFR2 
expression in the hippocampus as a consequence of TMEV infection. In addition, prior 
work has demonstrated that seizure incidence is dramatically reduced in TNFR1-/- mice 
(Kirkman et al., 2010). Therefore, we hypothesized that pharmacological inhibition of 
TNFR1 could decrease the incidence and/or severity of TMEV-induced acute seizures. 
TNFα is expressed as a homotrimeric transmembrane protein (tmTNFα) and the 
extracellular portion of tmTNFα can be cleaved by TNFα converting enzyme (TACE) to 
form a soluble TNFα (sTNFα). Both tmTNFα and sTNFα are active in their trimeric 
composition and mediate a variety of cellular activities via TNFRs (McCoy and Tansey, 
2008). sTNFα predominantly mediates its effects via TNFR1, while TNFR2 is fully 
activated only by tmTNFα (Grell et al., 1995; Grell et al., 1998). While anti-TNFα 
antibodies are approved for the treatment of peripheral inflammatory conditions, they do 
not cross blood brain barrier (BBB) (Tracey et al., 2008). Therefore, we selected the 




signaling through TNFR1 contributes to seizure generation. XPro1595 is a mutant form 
of human sTNFα and acts as a dominant-negative selective inhibitor of sTNFα (Steed et 
al., 2003). It dose-dependently exchanges with endogenous monomers of sTNFα to form 
an inactive heterotrimer which does not bind to TNFRs and lacks intrinsic bioactivity 
(Steed et al., 2003). Since sTNFα predominantly mediates its effects via TNFR1, 
XPro1595 indirectly inhibits TNFR1 functions. XPro1595 has been shown to provide 
beneficial effects in animal models of several peripheral as well as CNS inflammatory 
conditions including experimental autoimmune encephalomyelitis (EAE), Parkinson’s 
disease, spinal cord injury, and focal cerebral ischemia by selectively inhibiting sTNFα-
TNFR1 signaling and sparing beneficial functions of TNFR2 (Brambilla et al., 2011; 
Clausen et al., 2014; McCoy et al., 2006; Novrup et al., 2014; Zalevsky et al., 2007). 
Since the dosing regimen of 10 mg/kg of subcutaneous (s.c.) XPro1595 administered 
every third day was effective in models of other CNS diseases (Barnum et al., 2014; 
Brambilla et al., 2011; Clausen et al., 2014), we tested whether peripheral treatment of 
TMEV-infected mice with XPro1595 could prevent the development of handling-induced 
acute seizures. Handling sessions were captured by video monitoring and experimenters 
scoring seizures were blinded to the treatment groups as described in the methods. 
Administration of 10 mg/kg of XPro1595 (s.c.) at 1, 4, and 7 dpi did not decrease average 
number of seizures (Vehicle: 5.27 ± 0.37, XPro1595: 5.63 ± 0.45, n = 30, p=0.5313) or 
have any effect on average cumulative seizure burden at any time point during the acute 
seizure period when compared to vehicle-treated mice. To determine if the lack of 
efficacy on seizure incidence and severity was due to an inappropriate dosing regimen, 




h postinfection through 9 dpi. This dosing regime was also ineffective in decreasing 
either seizure frequency (Vehicle: 5.13 ± 0.71, XPro1595: 5.13 ± 0.77, n = 15, p=1.00) or 
severity. Finally, we increased the dose to 100 mg/kg and started treatment 2 days prior 
to infection through 7 dpi. Despite a 10-fold increase in the dose and initiating the 
treatment before infection, both XPro1595 and vehicle-treated groups had similar average 
numbers of seizures (Vehicle: 6.63 ± 1.24, XPro1595: 6.25 ± 0.77, n = 8, p=0.801) and 
average cumulative seizure burdens during the acute seizure period. Thus, systemic 
administration of high doses of XPro1595 was not effective in controlling seizures 
induced by TMEV infection. 
 
 
Lack of seizure control following CNS administration of  
 
XPro1595 on TMEV-induced acute seizures 
 
Despite numerous studies demonstrating central activity of XPro1595 in animal 
models of neurological disorders, a recent study found that systemic injection of 
XPro1595 was insufficient to provide therapeutic efficacy in a mouse model of spinal 
cord injury (SCI), whereas central administration of XPro1595 provided neuroprotection 
and ameliorated motor dysfunction in this model (Novrup et al., 2014). The concentration 
of XPro1595 in the CSF (1-6 ng/ml) has been found to be 1000-fold reduced compared to 
that in the plasma (1-8 µg/ml) from rats after 2-3 days of treatment with XPro1595 (10 
mg/kg, s.c.) (Barnum et al., 2014). Furthermore, as in the model of SCI, where acute 
inflammatory response occurs rapidly in the CNS, the protein levels of TNFα and other 
inflammatory cytokines increase rapidly in the hippocampus after TMEV infection. Thus, 




prevent signaling through the TNFR1 system following subcutaneous treatment in 
TMEV-infected mice Therefore, we tested the effectiveness of CNS administration of 
XPro1595 by free-hand bolus injection of 5 µl of XPro1595, equivalent to about 10 
mg/kg of mouse, at 2 dpi into the left lateral ventricle. Surprisingly, the average number 
of seizures was significantly reduced by treatment with XPro1595 (Vehicle: 5.6 ± 0.40, 
XPro1595: 3.1 ± 0.77, n = 10, p=0.0097), as well as average cumulative seizure burden at 
each day during 6-8 dpi (Figure 3.2a). However, the results could not be replicated when 
we repeated the free-hand i.c.v bolus experiment (average number of seizures, Vehicle: 
5.2 ± 0.63, XPro1595: 5.3 ± 0.79, n = 10, p=0.9222) (Figure 3.2b). Single bolus 
administration of XPro1595 might not have been sufficient to suppress endogenous 
TNFα during the entire acute seizure activity period. Therefore, mice were implanted 
with guide cannulas into the left lateral ventricle for multiple drug infusion in the CNS. 
Infusions of XPro1595 (10 mg/kg starting at 5-6 h after infection) or vehicle were 
repeated every other day for a total 4 infusions. As was observed following systemic 
injections, central administration of XPro1595 had no effect on either average number of 
seizures (Vehicle: 4.18 ± 1.32, XPro1595: 2.75 ± 1.02, n = 11-12, p=0.3952) or average 
cumulative seizure burden at any day during 3-8 dpi (Figure 3.2c, 3.2d) compared to 
TMEV-treated mice receiving vehicle infusions. The placement of the guide cannula into 
the ventricle was confirmed in all the mice enrolled for this study by infusing 0.1% 
Evan’s blue dye at 9 dpi (Figure 3.2e). Therefore, regardless of administration route, 
dosing regimen, or dose, XPro1595 was ineffective in preventing seizures following 







Differential susceptibility of TNFRs KO mice to develop  
 
TMEV-induced acute seizures 
 
Previous work has demonstrated that only 10% of TNFR1-/- mice (n = 2/20) 
infected with 2x104 PFU of TMEV developed acute behavioral seizures, suggesting that 
TNFR1-mediated effects could be involved in seizure generation in this model (Kirkman 
et al., 2010). As XPro1595 did not block acute seizures, we used transgenic animals to 
further test the hypothesis that TNFα signaling contributes to hyperexcitability following 
infection. Seizure incidence and severity in TNFα-/-, TNFR2-/-, and TNFR1-/-TNFR2-/- 
mice during the acute infection period was therefore evaluated (Figure 3.3). All the mice 
were infected with 2x104 PFU of TMEV to compare the data with the published findings 
in TNFR1-/- mice. Although the numbers of infected mice that developed acute 
behavioral seizures were similar for WT and TNFα-/- (67% seized mice, n = 18), seizure 
frequency and severity, as measured by average number of seizures and average 
cumulative seizure burden, were significantly reduced in TNFα-/- mice (Figure 3.3a). 
Interestingly, TNFR2-/- mice experienced severe seizures compared to WT as evidenced 
by an increase in the average (± SEM) number of seizures (WT: 2.8 ± 0.42, TNF2-/-: 4.6 
± 0.43, p=0.0042, n = 27 (WT), n = 30 (TNFR2-/-)) and an average cumulative seizure 
burden at 7 and 8 dpi (Figure 3.3b). The latency to develop the first seizure was also 
significantly reduced in TNFR2-/-, as 11 of 30 TNFR2-/- mice experienced seizures at 3 
dpi compared to just 1 of 27 WT mice. In addition, the overall percentage of seizure free-
mice for TNFR2-/- and WT mice over the entire acute seizure period was significantly 
different (p=0.0046) (Figure 3.3c). Since previous work demonstrated that TNFR1-/- mice 




developed severe TMEV-induced seizures, we reasoned that TNFR1-/-TNFR2-/- mice 
might have seizure patterns similar to WT mice. However, TNFR1-/-TNFR2-/- exhibited a 
significantly reduced average number of seizures (WT: 3.1 ± 0.50, TNFR1-/-TNF2-/-: 1.0 
± 0.34, p=0.001, n = 28 (WT), n = 30 (TNFR1-/-TNFR2-/-)) as well as average cumulative 
seizure burden at 6, 7, and 8 dpi (Figure 3.3d) compared to WT mice. The percentages of 
total numbers of infected mice that developed acute behavioral seizures in TNFR1-/-, 
TNFR1-/-TNFR2-/-, TNFα-/-, WT, and TNFR2-/- were 10% (n = 2/20) (Kirkman et al., 
2010), 33% (n = 10/30), 67% (n = 12/18), 73% (n = 40/55), and 93% (n = 28/30), 
respectively (Figure 3.3e). Both male and female mice had similar seizure responses in 
all the strains tested, and thus, the data from both genders are pooled. In contrast to the 
lack of seizure control observed with XPro1595 treatment, results in the transgenic 
mouse strains suggest that TNFα signaling through the TNFR1 pathway could indeed be 
a prominent mechanism through which hyperexcitability and seizure activity occur 
following TMEV infection. In addition, TNFα signaling through the TNFR2 pathway, as 
is the case in other neurological disorders, may be involved in dampening excitability, 
since mice lacking TNFR2 have a higher incidence and greater severity of seizures.  
 
 
Increase in the surface levels of AMPAR subunits  
 
during acute seizures in WT B6 mice 
 
AMPARs are the primary glutamate receptors that mediate fast excitatory 
neurotransmission in the brain (Traynelis et al., 2010). TNFα has been shown to increase 
AMPAR trafficking into postsynaptic neuronal membranes via neuronal TNFR1 (Beattie 




the amplitudes of mEPSCs are increased during the acute infection period in CA3 
pyramidal neurons, suggesting an increase in AMPA receptor surface expression (Smeal 
et al., 2012). Given the hypothesized role of TNFα in AMPAR trafficking and the 
observed increase in mEPSC amplitudes following TMEV infection, we evaluated 
hippocampal AMPA receptor expression using a cell surface biotinylation assay in mice 
treated with TMEV. Biotinylated surface proteins were separated from nonbiotinylated 
intracellular proteins using avidin beads in tissue prepared from acute hippocampal slices 
obtained from TMEV- and PBS-treated mice at 5 dpi as described here (Gabriel et al., 
2014). The GluA1 and GluA2 subunits of AMPARs were probed in the surface protein 
(SP) as well as in the total protein (TP) fractions by western blot (Figure 3.4a). The ratios 
of surface/total levels of GluA1 that indicate the relative levels of GluA1 present on the 
cell surface were significantly elevated in the TMEV-infected mice with seizures 
compared to control (OD: 0.31 ± 0.011 vs. 0.45 ± 0.018, p<0.0001, n = 6). We also 
probed for phosphate-activated glutaminase (PAG), a mitochondrial protein, to control 
for the biotinylation of intracellular proteins. The levels of PAG in the SP fraction were 
less than 5% compared to those in the TP fraction (OD: 0.015 ± 0.0026 in PBS, 0.03 ± 
0.0015 in TMEV) indicating that the biotinylation was largely restricted to cell surface 
proteins. The surface/total ratio for the levels of GluA2 was also significantly increased 
in TMEV-infected mice compared to control (OD: 0.53 ± 0.018 vs. 0.7 ± 0.025, 
p=0.0007, n = 6) (Figure 3.4b). The cell surface levels of GluA1 and GluA2 subunits 
were increased by 48% (p<0.0001) and 33% (p=0.0002), respectively, in TMEV-infected 
mice compared to PBS-injected mice (Figure 3.4c). The total protein levels of GluA1 and 




respectively, compared to control mice (Figure 3.4d). Since TMEV-infected mice have a 
pronounced neuronal loss in the CA1 region, it is not surprising that the total protein 
levels of GluA1 and GluA2 are decreased in TMEV-infected mice.  
Since TNFR2-/- mice had severe acute seizures compared to WT mice, we also 
conducted cell surface biotinylation assay in TNFR2-/- mice to test if TNFR2-/- mice had 
higher cell surface levels of GluA1 and GluA2 at 5 dpi. Similar to TMEV-infected WT 
C57BL/6J mice, the ratios of surface/total levels of GluA1 and GluA2 were significantly 
elevated in the TMEV-infected TNFR2-/- mice with seizures compared to PBS-injected 
TNFR2-/- mice (For GluA1, OD: 0.28 ± 0.012 vs. 0.40 ± 0.021, p=0.0011, n = 6; and for 
GluA2, OD: 0.45 ± 0.016 vs. 0.61 ± 0.036, p=0.0049, n = 6) (Figure 3.5a, 3.5b). The cell 
surface levels of GluA1 and GluA2 subunits were increased by 44% (p=0.0011) and 34% 
(p=0.0049), respectively, in the TMEV group compared to control mice (Figure 3.5c). 
The total protein levels of GluA1 and GluA2 in the TMEV-infected TNFR2-/- mice were 
significantly reduced by 42% and 48%, respectively, compared to control mice (Figure 




mEPSCs recorded in DGCs are not affected by TMEV infection 
 
TMEV exhibits a strong tropism for limbic brain regions and viral particles can be 
detected in CA1 and CA2 regions of hippocampus in the first week of infection (Buenz et 
al., 2009; Kirkman et al., 2010; Stewart et al., 2010b). Abundant c-Fos immunoreactivity, 
an indirect marker for neuronal activation, was found in the CA3 region and the dentate 




2012). Since the CA1 region is severely damaged by TMEV within 4-5 days of infection, 
initial studies investigating hyperexcitability in the hippocampus were focused on the 
CA3 region. Patch-clamp studies in acute brain slices found an increase in the amplitude 
and frequency of spontaneous and miniature EPSCs in CA3 pyramidal neurons during the 
period of 3-7 days post-TMEV infection (Smeal et al., 2012). The DG is another key 
region of the hippocampus that is frequently involved in seizure generation in limbic 
epilepsy models (Sloviter et al., 2012). Further, TNFα and TNFRs regulate homeostatic 
synaptic plasticity by enhancing excitatory synaptic strength in the DGCs in response to 
denervation-induced injury (Becker et al., 2015; Becker et al., 2013). Given our finding 
that there is an increased ratio of cell surface to total AMPA receptors in the biotinylation 
studies, we performed whole cell patch clamp recordings in DGCs to determine if there 
was an increase, as observed in CA3, in excitatory synaptic transmission during the acute 
infection period when seizures are observed. Miniature EPSCs in DGCs in hippocampal 
brain slices were obtained the during acute seizure period. Representative traces of 
mEPSCs from control and TMEV-infected mice are shown in Figure 3.6a. A total of 11 
DGCs from 8 mice in the control group and 15 DGCs from 10 TMEV-infected mice with 
acute seizures were included in the analysis. The cumulative fraction analysis of mEPSC 
amplitude as well as interevent interval found no significant differences between 
treatment groups (p>0.05, KS test) (Figure 3.6b, 3.6c). The average (± SEM) mEPSC 
amplitudes were 14.3 ± 0.66 pA and 14.9 ± 0.59 pA in the control and TMEV mice, 
respectively (p=0.5), and the average (± SEM) frequencies were 2.30 ± 0.36 Hz and 2.35 
± 0.23 Hz for the control and TMEV mice, respectively (p=0.9). These data suggest that, 









The present series of experiments evaluated the role of TNFα signaling in the 
hippocampus, a brain region involved in seizure generation, following TMEV infection. 
TNFα and its effects mediated via the activation of TNFR1, and/or reduced signaling 
through TNFR2, could be one of the major inflammatory pathways contributing to acute 
seizures. We demonstrate here, for the first time, that there is a substantial increase in the 
protein level of TNFα that is coincident with an increase in the protein expression ratios 
of TNFR1:TNFR2 in the hippocampus. The role of TNFα in contributing to seizure 
generation following TMEV infection was also supported by our findings in a number of 
transgenic mice. We found that there is a decrease in the seizure incidence, frequency, 
and severity of acute seizures in TNFR1-/- and TNFR1-/-TNFR2-/- mice, whereas there is 
an increase in frequency and severity of acute seizures in TNFR2-/- mice. In addition, 
consistent with the hypothesized role of TNFα in hippocampal AMPA receptor 
trafficking, we demonstrated that there is a significant increase in the cell surface to total 
AMPA receptor ratio in TMEV transfected mice. This increase in cell surface expression 
likely underlies the increased amplitudes of mEPSCs that we have previously observed in 
recordings obtained in CA3 pyramidal cells in brain slices obtained from TMEV-infected 
mice (Smeal et al., 2012). While peripheral as well as central administration of 
XPro1595, an inhibitor of sTNFα, failed to inhibit TMEV-induced acute seizures, the 
data acquired here from WT and transgenic animals suggests that signaling through the 




period and may serve as an important therapeutic target in conditions in which 
inflammation contributes to seizure generation.  
TNFα signaling contributes to the regulation of homeostatic synaptic plasticity by 
modulating the postsynaptic surface levels of AMPARs under physiological conditions 
(Beattie et al., 2010). TNFα has been shown to induce synaptic scaling via neuronal 
TNFR1 by increasing the cell surface expression of GluA1-containing and GluA2-
lacking AMPARs in cultured hippocampal neurons (Beattie et al., 2002; Stellwagen et 
al., 2005; Stellwagen and Malenka, 2006), in the rat hippocampal slice preparation 
(Stellwagen et al., 2005; Stellwagen and Malenka, 2006), in an animal model of SCI 
(Ferguson et al., 2008), and also in the dorsal spinal cord neurons in an intraplantar 
carrageenan model of inflammatory pain (Choi et al., 2010). Elevated levels of AMPARs 
in postsynaptic membranes can increase the strength of excitatory synaptic transmission. 
Furthermore, GluA2-lacking AMPARs are Ca2+-permeable and increased intracellular 
concentration of Ca2+ can result into excitotoxicity (Liu and Zukin, 2007). We report that 
the levels of GluA1 and GluA2 subunits of AMPARs on the cell surface are elevated in 
the hippocampus of mice with acute seizures compared to noninfected mice. Differences 
in the trafficking of GluA2 subunits between SCI, pain models, and the present study 
may reflect the differences in underlying pathological, anatomical, and experimental 
conditions. Indeed, TNFα has been shown to exert varying effects on the regulation of 
excitatory synaptic strength contingent upon factors such as brain region. TNFα drives 
the internalization of GluA1 and GluA2 subunits of AMPARs in the medium spiny 
neurons in striatum, which is in contrast to its effects in hippocampal neurons (Lewitus et 




AMPAR subunits most likely occurs in CA3 pyramidal neurons because 1) AMPA 
receptors are expressed in principal cells of the hippocampus (Osten et al., 2006), 2) CA1 
pyramidal neurons start to degenerate by 3 dpi and exhibit extensive loss by 4 dpi 
(Loewen et al., 2016), 3) significant increases in amplitude and frequency of mEPSCs 
recorded from CA3 pyramidal neurons in TMEV-infected mice with seizures between 3-
7 dpi (Smeal et al., 2012), and 4) no change in mEPSCs in DGCs in TMEV-infected mice 
with seizures between 3-7 dpi. AMPARs are also present in glial cells although with 
much less density than in neurons (Traynelis et al., 2010), and hippocampal interneurons 
express mainly GluA1 and GluA4, but lack GluA2 (Osten et al., 2006); therefore, we do 
not rule out the possibility of some postsynaptic AMPAR dynamics in these cells. A 
novel approach for real-time in vivo monitoring of AMPAR subunits has recently been 
described (Zhang et al., 2015), which could be utilized to address the question of spatial 
and cellular subunit targeting in the hippocampus where AMPAR trafficking occurs 
during TMEV-induced seizures.  
TNFR1-/- and TNFR1-/-TNFR2-/- mice were found to be highly resistant to 
developing TMEV-induced acute seizures, and those with seizures had much less severe 
seizures compared to WT mice. In addition, although the percentage of TMEV-infected 
TNFα-/- mice developing acute seizures was similar to WT mice, frequency and severity 
were significantly reduced in TNFα-/- mice. Taken together with the AMPAR trafficking 
findings, we conclude that TNFα is likely implicated in synaptic scaling via TNFR1 
resulting in hippocampal hyperexcitability and seizures. However, additional studies that 
utilize pharmacological approaches to modulate the level of TNFα and the functions of 




increased levels of TNFα impact excitatory strength and seizure generation.  
Inhibition of sTNFα-TNFR1-mediated effects and sparing tmTNFα-TNFR2-
mediated effects of TNFα has been a well-rationalized strategy to treat many peripheral 
and CNS inflammatory conditions which also minimizes adverse effects associated with 
absolute inhibition of TNFα (Fischer et al., 2015). In previous studies, the concentration 
of XPro1595 in CSF and plasma were found to be 1-6 ng/ml and 1-8 µg/ml, respectively, 
following subcutaneous treatment of rats with 10 mg/kg XPro1595 (Barnum et al., 2014). 
A 10-fold higher level of XPro1595, such as used in the present experiments, should 
therefore exchange 99% of endogenous sTNFα (Steed et al., 2003). In the present studies, 
the average concentration of TNFα in the hippocampus was 110.5 pg/ml at 5 days post-
TMEV infection in mice with acute seizures. Thus, if the CSF concentration of XPro1595 
in rats after 10 mg/kg s.c. dosing could be extrapolated to TMEV-infected mice, 10 
mg/kg s.c. dosing should have been sufficient to remove the endogenously active form of 
sTNF. The present finding that XPro1595 treatment was unable to influence TMEV-
induced seizures could be due to an insufficient concentration of XPro1595 in the 
hippocampus. This could also have been the limitation in a recent study where only CNS, 
but not peripheral, administration of XPro1595 had beneficial effects in the mouse model 
of SCI (Novrup et al., 2014). However, multiple i.c.v. infusion of XPro1595 also failed to 
reduce TMEV-induced seizures in the present study. Further data on the 
pharmacokinetics of XPro1595 in TMEV-infected mice could facilitate a better design of 
dosing regimen for treatment with this compound. However, even if XPro1595 
sufficiently removed endogenous sTNFα, TNFR1 may still be activated by tmTNFα. 




inflammation and cytotoxicity through TNFR1 (Horiuchi et al., 2010). For example, a 
recent study using XPro1595 to prevent peripheral inflammation in a model of gout 
determined that the inflammatory response observed in that model was independent of 
sTNFα and was likely due to tmTNFα (Amaral et al., 2016). Thus, XPro1595 was unable 
to prevent the inflammation observed in that model. In addition, lymphotoxin (LTα3), 
formerly known as TNFβ, is structurally similar to sTNFα and binds to both TNFRs 
(Tracey et al., 2008). LTα3-TNFR1 signaling can cause inflammation similar to sTNFα-
TNFR1 effects which could partly explain the lack of effects of XPro1595 on TMEV-
induced seizures. Several TNFR1-specific inhibitors are under development (Fischer et 
al., 2015), which should be leveraged in the future to test the hypothesis of a pathogenic 
role of TNFR1-mediated signaling in TMEV-induced seizures. Finally, it has been found 
in previous studies that IL-6 signaling can also contribute to seizure generation during the 
TMEV acute infection period (Kirkman et al., 2010; Libbey et al., 2011). Animals 
deficient in IL-6, or treated with wogonin to reduce infiltrating macrophages, which are 
the major source of IL-6 (Cusick et al., 2013), also have a decrease in acute seizure 
activity in this model (Kirkman et al., 2010). Therefore a polytherapy approach involving 
both TNF and IL-6 modulators may prove the most efficacious in preventing seizure 
activity following TMEV infection. 
In addition to increasing AMPAR trafficking to the synaptic membrane, TNFα 
has been proposed to increase excitation by modulating the functions of astrocytes. 
Pathogenic levels of TNFα in hippocampus may induce the release of glutamate from 
astrocytes into the synapse where glutamate can bind to presynaptic NMDA receptors to 




2011). TNFα has also been shown to decrease expression of the astrocyte glutamate 
transporter (GLT1) (Carmen et al., 2009). Recently, TNFα has been demonstrated to 
downregulate connexin-43 and GLT1 on spinal astrocytes, causing increased 
glutamatergic neurotransmission and neuropathic pain in mice (Morioka et al., 2015). 
Astrogliosis occurs throughout the hippocampus within 3 days of TMEV infection and 
persists up to 4-6 months postinfection (Loewen et al., 2016; Stewart et al., 2010a). It is a 
matter of future interest to determine if increased levels of TNFα affect the expression of 
glutamate transporters and gap junction proteins on astrocytes to tip the balance of 
synaptic function in favor of hyperexcitatory conditions.  
Our results that TNFα contributes to neuronal hyperexcitability in the 
hippocampus through TNFR1-mediated signaling, whereas TNFR2-mediated signaling 
imparts antiictogenic effects, are not specific to the TMEV model. Similar diametric roles 
of TNFRs in modulating seizure activity have been reported in kainic acid and kindling 
models of limbic seizures (Weinberg et al., 2013). Our results also corroborate clinical 
findings in which the levels of TNFR1 and TNFR1-signaling proteins are increased in the 
resected hippocampal tissues from patients with refractory TLE (Yamamoto et al., 2006). 
Although animal studies that investigate the role of the TNFα system in various models 
of limbic seizures suggest that TNFR1-mediated signaling contributes to ictogenic 
effects, the consequences of pathogenic levels of TNFα on seizures are highly context-
dependent. For example, overexpression of murine TNFα in astrocytes decreased kainate-
induced seizures (Balosso et al., 2005), whereas overexpression of murine TNFα in 
neurons either caused seizures (Probert et al., 1995) or had no effects on kainate-induced 




and the type of TNFα, the cell types expressing TNFRs, levels of TNFα and relative 
density of TNFRs in the tissue can influence the seizure outcome (Probert, 2015). These 
factors must be investigated in detail by designing animal studies that reflect clinical 
findings from the patients with TLE.  
In conclusion, we have demonstrated that pathogenic level of TNFα and an 
increase in the expression ratio of TNFR1:TNFR2 in the hippocampus are associated 
with acute behavioral as well as focal hippocampal electrographic seizures in TMEV-
infected mice. TNFα might cause hyperexcitation in TMEV-infected mice by 
strengthening excitatory synapses via a TNFR1-mediated mechanism, whereas TNFR2 
may provide antiictogenic effects during acute infection. Inflammation occurs in other 
models of epilepsy and many patients with epilepsy present with CNS inflammatory 
conditions. Antiinflammatory therapies could be useful as stand-alone therapy or in 
combination with antiseizure medications. Anti-TNFα antibodies are widely prescribed 
for peripheral inflammatory conditions, however, they also cause serious adverse effects 
by inhibiting desirable functions of TNFα (Traynelis et al., 2010). Therefore, TNFR1-
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Figure 3.1 Increase in the levels of TNFα and in a ratio of the protein expression of 
TNFR1:TNFR2 in the hippocampus of TMEV-infected mice during acute seizure activity 
period. (a) mRNA levels of TNFα, as measured by RT-qPCR, are significantly increased 
in TMEV-infected mice at 5 and 14 days postinfection (dpi) by 161- and 88-fold, 
respectively, compared to PBS-infected control mice (n = 4 for TMEV and control). (b) 
206- and 35-fold increase in the protein expression levels of TNFα in TMEV-infected 
mice at 5 and 14 dpi compared to the PBS-injected control mice (Control: n = 5; TMEV: 
n = 8 (1 dpi), 6 (5 dpi), and 5 (14 dpi)). (c) Representative immunoblot shows the protein 
expression of TNFR1, TNFR2, and actin in the hippocampus from PBS- and TMEV-
infected mice (n = 3). (d) Densitometric analysis of the immunoblots shows the 
expressions of TNFR1 and TNFR2 normalized to the expression levels of actin (Control: 
n = 5; TMEV: n = 5 (1 dpi), 6 (4 and 14 dpi); O.D., Optical density). The relative 
expression levels of TNFR1 and TNFR2 (TNFR1:TNFR2) are significantly increased by 
1.54- and 2.1-fold at 4 and 14 dpi, respectively, in the TMEV-infected mice compared to 
control mice. (e-g) Comparison of mRNA and protein levels of TNFR1 and TNFR2 in 
the hippocampus of TMEV-infected mice before (1 dpi), during (5 dpi), and after (14 dpi) 
acute seizures. The ratio of TNFR1 to TNFR2 for mRNA is significantly reduced during 
the acute infection period (g, upper panel), whereas the ratio for the protein expression is 
significantly increased over the acute infection period (g, lower panel). The data are 
shown as mean ± SEM. Statistics: Two-way ANOVA followed by Bonferroni posttest; 












Figure 3.2 CNS administration of XPro1595 does not affect TMEV-induced acute seizure 
frequency and intensity. (a) Single i.c.v. bolus administration of XPro1595 (10 mg/kg) at 
2 dpi in TMEV-infected mice (n = 10) significantly reduces an average number of 
generalized tonic-clonic seizures and an average cumulative seizure burden starting from 
6 dpi compared to vehicle-treated TMEV-infected mice. (b) The repetition of single i.c.v. 
bolus administration study does not replicate the findings shown in (a). (c) Slow infusion 
of XPro1595 (10 mg/kg) at 0, 2, 4, and 6 dpi into the left lateral ventricle using a 
surgically implanted guide cannula does not reduce average seizure frequency and 
severity (n = 12, XPro1595; n = 11, vehicle). Each circle represents an individual mouse 
and the horizontal line shows average number of seizures per group. (d) Average seizure 
burden corresponding to each stage of modified Racine scale for generalized tonic-clonic 
seizures shows no difference between vehicle- and XPro1595-treated TMEV-infected 
mice. Only those mice which had acute seizures are included in this analysis. (e) The 
surgical placement of the guide cannula into the left lateral ventricle was confirmed by 
i.c.v. infusion of 0.1% Evans blue dye at 9 dpi in all TMEV-infected mice treated with 
either XPro1595 or vehicle. The panel shows an example of a diffusion of the dye into 







Figure 3.3 TMEV-induced acute behavioral seizure susceptibility in WT, TNFα-/-, 
TNFR2-/-, and TNFR1-/-TNFR2-/- mice. (a) TNFα-/- mice have a significant reduction in 
the seizure frequency (upper panel), plotted as a total number of seizures per mouse, and 
in the seizure severity (lower panel) as measured by an average cumulative seizure 
burden during acute seizure period (3-8 dpi) compared to WT mice. Each circle 
represents individual mouse and the horizontal line shows an average number of seizures 
per group. (b) TNFR2-/- mice show an increase in the average seizure frequency as well 
as severity. (c) Reduced latency to develop a first TMEV-induced acute seizure in 
TNFR2-/- mice compared to WT mice. (d) Reduced average seizure frequency and 
severity in TNFR1-/-TNFR2-/- mice. (e) Percentage of total infected mice that show acute 
behavioral seizures during 3-8 dpi. Statistics: unpaired t test (frequency), Scheirer-Ray-
Hare test (severity), Fisher’s exact test (% seized mice); and long-rank test (% seizure 







Figure 3.4 Increase in the cell surface levels of GluA1 and GluA2 subunits of AMPARs 
in TMEV-infected WT C57BL/6J mice during acute seizures. (a) Representative 
immunoblots from two mice show the levels of GluA1 in the total as well as the cell 
surface fractions of proteins isolated from ipsilateral hippocampus at 5 days postinjection 
of either PBS (control) or TMEV. Data in the first (total) and the third (surface) lanes 
from the left are from the same mouse, and the second (total) and the fourth (surface) 
lanes correspond to the other mouse. The surface proteins were isolated from the 
intracellular proteins by cell surface biotinylation procedure in acute hippocampal slices. 
The levels of GluA1 were quantified by densitometry and the data are shown as a ratio of 
surface to total protein which is significantly increased in TMEV-infected mice (n = 6). 
Phosphate-activated glutaminase (PAG) is a mitochondrial protein and serves as an 
intracellular control protein. (b) Similar to GluA1, the ratio of surface/total level for 
GluA2 is also increased in TMEV-infected mice (n = 6). (c) The ratios of surface/total 
protein expression for GluA1 and GluA2 are increased by 48% and 33%, respectively 
(data normalized to control). (d) About 50% decrease in the total expressions of GluA1 
and GluA2 in TMEV-infected mice compared to the control group. Statistics: Unpaired 







Figure 3.5 Increase in the cell surface levels of GluA1 and GluA2 subunits of AMPARs 
in TMEV-infected TNFR2-/- mice during acute seizures. (a) Representative immunoblots 
from two mice show the levels of GluA1 in the total as well as the cell surface fractions 
of proteins isolated from ipsilateral hippocampus at 5 days postinjection of either PBS 
(control) or TMEV. The surface proteins were isolated by cell surface biotinylation 
procedure in acute hippocampal slices. The levels of GluA1 were quantified by 
densitometry and the data are shown as a ratio of surface to total protein that is 
significantly increased in TMEV-infected mice (n = 6). Phosphate-activated glutaminase 
(PAG) is a mitochondrial protein and serves as an intracellular control protein. (b) 
Similar to GluA1, the ratio of surface/total level for GluA2 is also increased in TMEV-
infected mice (n = 6). (c) The ratios of surface/total protein expression for GluA1 and 
GluA2 are increased by 44% and 34%, respectively (data normalized to control). (d) 
About 50% decrease in the total expressions of GluA1 and GluA2 in TMEV-infected 







Figure 3.6 No difference in the properties of miniature excitatory postsynaptic currents 
(mEPSCs) of dentate granule cells (DGCs) between PBS-injected (control) and TMEV-
infected mice during acute seizure activity period. (a) Representative traces of mEPSCs 
measured in the DGCs from the control group and TMEV-infected mice during 3-7 dpi. 
(b) Cumulative fraction distribution of the amplitude of mEPSCs shows no difference 
between the control and the TMEV groups. Average amplitudes of mEPSCs are plotted 
in the lower panel (Control: n = 8, TMEV: n = 10). (c) Cumulative fraction distribution 
of the interevent interval (IEI) of mEPSCs shows no difference between both the 
treatment groups. The lower panel shows the average frequency of mEPSCs. Statistics: 






Table 3.1 Significant increase in the protein levels of various inflammatory mediators in 
the hippocampus of TMEV-infected mice during acute seizure activity period. Statistics: 
Two-way ANOVA, Bonferroni posttest, #p<0.05, *p<0.01, †p<0.001; SEM, standard 
error of the mean. (TNFα, tumor necrosis factor-α; IFNγ, interferon-γ; IL, interleukin; 
CXCL1, C-X-C motif chemokine ligand 1) 
 
Cytokine 
Fold change (relative to PBS-injected control mice) 
Average SEM Average SEM Average SEM 
1 dpi (n = 8) 5 dpi (n = 6) 14 dpi (n = 5) 
TNFα 6.9 0.6 206.2
† 14.9 34.8# 7.1 
IFNγ 4.5 0.8 21734.4† 3123.2 99.1 21.6 
IL-1β 6.9 1.1 58.2† 5.4 46.6† 13.5 
IL-10 2.3 0.3 47.2† 6.0 9.6 1.9 
IL-12p70 2.5 0.3 3.0# 0.5 6.0† 1.0 
IL-4 1.0 0.2 0.8 0.1 1.3 0.3 
IL-2 2.4 0.3 14.4† 4.2 4.9 0.7 
IL-5 2.0 0.1 10.8* 2.5 2.6 1.2 














CANNABIDIOL TREATMENT PREVENTS SEIZURES  
FOLLOWING CNS INFECTION WITH THEILER’S  





Theiler’s Murine Encephalomyelitis Virus (TMEV) infection in the CNS of 
C57BL/6J mice causes a robust inflammatory response and oxidative stress in the 
hippocampus that is coincident with an acute seizure activity period. This acute seizure 
period is followed by a latent period and the majority of mice exhibiting acute seizures go 
on to develop epilepsy (Stewart et al., 2010). Protein levels of several cytokines and 
chemokines, including TNFα, IFNγ, IL-1β, IL-6, IL-2, IL-5, IL-12, and CXCL1, are 
significantly increased in the hippocampus of TMEV-infected mice during the acute 
behavioral seizure period (Table 3.1) (Cusick et al., 2013; Kirkman et al., 2010). In 
addition, mice deficient in TNFR1, TNFα, or IL-6 are much less susceptible to 
developing TMEV-induced acute seizures compared to WT mice (Figure 3.3a) (Kirkman 
et al., 2010). Oxidative and nitrative stress markers, such as elevated levels of 3-
nitrotyrosine and impaired glutathione redox status, as evidenced by a decrease in the 
ratio of GSH:GSSG, have also been observed in the hippocampus of TMEV-infected 




redox changes in the brain following TMEV infection may contribute to the development 
of acute seizures. Previous studies investigated the cellular sources of inflammatory 
mediators in the brain during acute TMEV infection period. In the CNS, glial cells, 
especially microglia, are the major source of cytokines and chemokines. In addition, 
neurons, endothelial cells, and infiltrating peripheral immune cells can also release 
inflammatory molecules under pathogenic conditions in the brain (Vezzani et al., 2011). 
Microgliosis, astrogliosis, and infiltration of macrophages have all been shown to occur 
in the hippocampus of TMEV-infected mice during acute seizures and thus likely 
contribute to the observed inflammatory response (Cusick et al., 2013; Loewen et al., 
2016). Microglia and infiltrating macrophages are the major sources of TNFα and IL-6, 
respectively, in TMEV-infected mice with acute seizures (Cusick et al., 2013). Inhibiting 
infiltration of macrophages and microgliosis by minocycline or wogonin treatment has 
been shown to decrease the numbers of TMEV-infected mice that developed acute 
seizures (Cusick et al., 2013; Libbey et al., 2011). This further supports that inflammation 
likely plays a significant role in driving seizures in TMEV-infected mice, thus, 
antiinflammatory therapies, either as monotherapy and/or in combination with antiseizure 
drugs (ASDs), could be effective in reducing acute seizures and perhaps even prevent the 
development of epilepsy in TMEV-treated mice.  
Cannabidiol (CBD), a nonpsychogenic phytoconstituent of the Cannabis sativa 
plant, has recently attracted clinical interest for the treatment of drug refractory epilepsy 
(Friedman and Devinsky, 2015). CBD imparts antiseizure effects in several animal 
models by altering neuronal excitability through a variety of mechanisms at doses devoid 




al., 2015). CBD may also modulate neuronal excitability by decreasing presynaptic 
release of glutamate by inhibiting G-protein-coupled receptor 55 (GRP55)-mediated 
release of intracellular Ca2+ (Sylantyev et al., 2013). CBD can also exert antioxidant and 
antiinflammatory effects (Burstein, 2015; Rosenberg et al., 2015). CBD decreases the 
release of TNFα in lipopolysaccharide-treated rats (Liou et al., 2008). CBD is also known 
to decrease the levels of other proinflammatory cytokines including IL-2, IFNγ, IL-6, IL-
12p40, and IL-17 in mice (Hegde et al., 2011). Furthermore, CBD can enhance adenosine 
signaling by inhibiting adenosine uptake mechanisms (Carrier et al., 2006; Liou et al., 
2008). Adenosine is known to function as an endogenous immunosuppressant (Hasko and 
Cronstein, 2004) and can also directly inhibit seizures and confer neuroprotective effects 
(Boison, 2012); therefore, CBD may also suppress inflammation and seizure activity 
through these mechanisms. In addition, CBD can ameliorate behavioral symptoms in an 
experimental autoimmune encephalomyelitis mouse model of multiple sclerosis 
potentially by suppressing T cell proliferation and microglial activity in the spinal cord 
(Kozela et al., 2011). CBD treatment also provides long-term improvement in motor 
deficits in TMEV-induced demyelinating disease, a model of multiple sclerosis in SJL/J 
mice, by decreasing infiltration of leukocytes, microglial activation, and proinflammatory 
cytokines IL-1β and TNFα (Mecha et al., 2013). Finally, isobolographic studies 
conducted by Dr. Misty D. Smith (University of Utah) found synergistic effects with 1:1 
combination of CBD and levetiracetam in the 6 Hertz (6 Hz) psychomotor seizure test 
using CF1 mice (Smith et al., 2015). Based on these data, we hypothesized that CBD 
could be effective in suppressing acute behavioral seizures following TMEV infection. 




behavioral seizures in the TMEV model in C57BL/6J mice. While low doses of CBD had 
no effect on acute seizures that were induced by TMEV infection, the highest dose of 
CBD (180 mg/kg) significantly reduced the frequency and severity of acute seizures. The 
time to peak effect (TPE) of CBD in the 6 Hz psychomotor seizure test was observed at 2 
h post-CBD treatment. This suggests that the lack of observed effects at the lower doses 
of CBD may have been due to the time at which animals were tested. Nevertheless, the 
results reported herein suggest that CBD may prove to be efficacious in this model of 







Male C57BL/6J mice (#006460) aged 5-6 weeks were purchased from Jackson 
Laboratory. After arrival, mice were allowed to acclimatize for at least 3 days prior to the 
experiment. Mice were provided food and water ad libitum and kept in a facility 
providing a 12 h light/dark cycle starting at 6:00 AM. All the procedures performed were 
in accordance with the guidelines provided and approved by the Institutional Animal 
Care and Use Committee of the University of Utah. 
 
 
Method of TMEV infection and seizure monitoring 
 
Mice are briefly anesthetized with 3% isoflurane and injected with 20 µl of either 
phosphate-buffered saline (PBS) or 2x105 PFU (plaque forming units) DA-TMEV 
solution intracortically in the right hemisphere by inserting the needle at a 90° angle to 




imaginary line connecting the eye and the ear. A sterilized syringe containing a plastic 
jacket on the needle exposing 2.5 mm of needle is used for infection to restrict the 
injection site to the somatosensory cortex. 
Acute behavioral seizures were induced by briefly agitating the mice by shaking 
their cages and the seizures were video-monitored twice daily at 11:00 AM and at 4:00 
PM between 2 to 8 days postinfection (dpi). Seizure intensity was graded using modified 
Racine scale as follows: stage 1, mouth and facial movements; stage 2, head nodding; 
stage 3, forelimb clonus; stage 4, forelimb clonus, rearing; stage 5, forelimb clonus, 
rearing, and falling; and stage 6, intense running, jumping, repeated falling, and severe 
clonus. Seizure scores were assigned after verifying seizure video recordings by an 
investigator blinded to the treatment groups. Seizure frequency was reported as the 
average number of seizures during the entire acute seizure period, whereas seizure 
severity/intensity was represented as the average cumulative seizure burden at each dpi 
during the acute seizure period. Cumulative seizure burden at each dpi for a mouse was 
calculated by summing all of the seizure score numbers up to that dpi. 
 
 
CBD treatment  
 
CBD was received from the National Institute on Drug Abuse (NIDA). Since 
CBD does not dissolve in aqueous solvents, it was formulated as an oil-in-water emulsion 
using a mixture of 100% ethanol, Kolliphor®, and 0.9% saline (1:1:18). CBD was first 
dissolved in 100% ethanol and equal amount of Kolliphor® (polyoxyl castor oil, BASF) 
was added. The mixture was vortexed and a small amount of 0.9% saline was added 




emulsion. The mixture of CBD in 100% ethanol and Kolliphor® appears transparent and 
after addition of a small amount of 0.9% saline, the emulsion appears milky. The 
emulsion was kept on ice and vortexed immediately before injecting each mouse i.p. at 
10 ml/kg. Since the CBD emulsion destabilizes after about 1 h of preparation, it was 





The dataset involving continuous variables is represented by the mean and 
standard error of the mean (SEM), and the dataset with ordinal variables is presented as a 
frequency distribution. Experimental design involving two groups with one continuous 
dependent variable was analyzed by unpaired two-tailed t test, whereas design involving 
two categorical independent variables and one continuous dependent variable was 
analyzed by two-way ANOVA. Multiple comparisons were performed by Bonferroni 
posttest. Cumulative seizure burden, which was calculated from a ranked dataset, was 
analyzed by the Scheirer-Ray-Hare test, which is an extension of Kruskal-Wallis test for 
two randomized factorial designs (Scheirer et al., 1976). The statistical calculations were 





High dose CBD (180 mg/kg) effectively reduces TMEV-induced  
 
acute seizure frequency and intensity 
 
The ED50 of CBD had been calculated previously in the 6 Hz seizure model of 




different doses of CBD, ranging from 25-300 mg/kg i.p., and subjected to the 6 Hz 
psychomotor seizure test, and the numbers of mice protected from seizures, that is, an 
absence of jaw chomping, twitching of vibrissae, and forelimb clonus, were determined 
(Barton et al., 2001). From this dose-response study, the ED50 of CBD was calculated to 
be 180 mg/kg by probit analysis. Therefore, we used this dose to determine the 
antiseizure potential of CBD in the TMEV-induced infection model.  
The first dosing regimen chosen for treatment with CBD was a “prophylactic” 
approach. CBD administration was begun two days prior to TMEV infection and 
continued for 8 days after infection. Therefore, as shown in Figure 4.1a, mice were 
treated with CBD (180 mg/kg; i.p. twice daily every 12 h) for a total 10 days. Acute 
seizures were video-monitored and assessed using a modified Racine seizure scale from 
stage 3 to 6 as described in the Methods and represented as a heat map (Figure 4.1b). All 
TMEV-infected mice in the vehicle treatment group developed acute seizures, whereas 3 
mice in the CBD group did not have seizures. CBD-treated mice had a dramatic reduction 
in the average number of seizures that occurred over the acute seizure period (CBD: 1.5 ± 
0.40, Vehicle: 8.3 ± 0.73, n = 10, p<0.0001. Data are presented as average seizures ± 
SEM.) (Figure 4.1c) and seizure severity between 4-8 dpi (Figure 4.1d) compared to 
vehicle-treated mice. Although 70% of CBD-treated mice had at least one behavioral 
seizure, CBD treatment delayed the development of seizures and significantly prolonged 
the seizure freedom period (p<0.0001, log-rank test) (Figure 4.1e).  
After observing beneficial effects of CBD in the prophylactic regimen, we treated 
TMEV-infected mice with a more relevant therapeutic treatment regimen. Instead of 




infection. A significant portion of TMEV-infected mice begin to have acute seizures on 3 
dpi, so the mice were treated with CBD between 3-7 dpi (Figure 4.2a). As in the first 
study, CBD was administered at 7:00 AM and 7:00 PM and seizures were evaluated at 4 
and 9 h after the morning injection. The seizure scores for all the mice are presented in 
the heat map (Figure 4.2b). In both treatment groups, mice had similar numbers of 
seizures on 3 dpi (the first day of treatment). However, the seizure frequency and severity 
were dramatically reduced in the CBD group at 4 dpi and these effects were continued 
during the remaining period of CBD treatment. Average number of seizures was reduced 
by 67% in CBD-treated mice compared to vehicle-treated mice (CBD: 2.4 ± 0.60, 
Vehicle: 6.6 ± 0.75, n = 10, p=0.0004. Data are presented as average seizures ± SEM.) 
(Figure 4.2c). In addition, seizure severity was also significantly decreased in the CBD-
treated mice between 5-8 dpi (Figure 4.2d). In contrast to the prophylactic treatment 
regimen, analysis of seizure freedom over time postinfection found no difference between 
the treatment groups in this treatment regimen (p=0.3751, log-rank test) since the 
majority of the mice in both the groups developed seizures within 3-4 dpi (Figure 4.2e).  
 
 
Lower CBD doses have no effect on  
 
TMEV-induced acute seizures 
 
Next we conducted a dose-response study to determine the ED50 of CBD in this 
model. Mice were divided into 6 groups (n = 10), with 5 of the groups being treated with 
different doses of CBD (22.5, 45, 90, and 180 mg/kg) or vehicle starting at 3 dpi through 
7 dpi every 12 h. One group served as noninfected control and only injected with PBS 




reducing the average number of seizures (Vehicle: 10.2 ± 0.68, 22.5 mg/kg CBD: 8.3 ± 
0.70, 45 mg/kg CBD: 9.6 ± 1.02, 90 mg/kg CBD: 10.1 ± 0.94, and 180 mg/kg CBD: 4.4 
± 0.85. Data are presented as average seizures ± SEM.) and average cumulative seizure 
burden compared to TMEV-infected vehicle-treated mice. However, as shown 
previously, the high dose of CBD (180 mg/kg) consistently reduced seizure frequency 
(p<0.0001 compared to vehicle, 45 and 90 mg/kg groups, p<0.05 compared to 22.5 
mg/kg group) (Figure 4.3a) and the average cumulative seizure burden from 4-7 dpi was 
also significantly reduced compared to the vehicle treated group (Figure 4.3b).  
Although CBD (180 mg/kg) was efficacious in reducing TMEV-induced seizures, 
mice treated with this dose of CBD lost weight starting from 4 dpi through 9 dpi 
compared to mice in the other treatment groups (Figure 4.3c). Weight loss was coincident 
with the CBD treatment period as mice started to recover after 8 dpi. CBD (180 mg/kg)-
treated mice were also observed to have ruffled fur, which may suggest a hypothermic 
effect of treatment, and hypothermia can contribute to a reduction in seizures (Guilliams 
et al., 2013; Wang et al., 2011). Therefore, we measured body temperature of CBD (180 
mg/kg)-treated mice up to 4 h post-CBD treatment from 3-7 dpi by a rectal temperature 
probe. As shown in Figure 4.3d, average body temperature measured immediately before 
CBD treatment (baseline) ranged from 37.5 to 38.3 °C. On 3 dpi, the average body 
temperature was reduced by 3.4 °C from the baseline at 2 h post-CBD treatment and that 
could be considered mildly hypothermic, however, the temperature quickly recovered by 
4 h post-CBD treatment. While a reduction in average body temperature of up to 2.1 °C 
occurred at 2 h post-CBD treatment everyday from 4-7 dpi, that extent of a temperature 




seizure frequency and severity were similar between CBD (180 mg/kg)-treated mice and 
vehicle-treated mice on 3 dpi, but significantly reduced during 4-7 dpi (Figure 4.2b). 
Therefore, these data suggest that hypothermia likely did not contribute to the observed 
decrease in acute seizures. Mechanism(s) for the antiseizure effects of the high dose of 
CBD (180 mg/kg) are currently unknown and should be investigated in future studies.  
In an additional set of experiments, we tested the efficacy of 135, 150, and 165 
mg/kg CBD in reducing TMEV-induced acute seizures. None of these additional three 
doses had any effect on either the average number of seizures or the average cumulative 
seizure burden when compared to the TMEV-infected vehicle treatment group (Figure 
4.4a, 4.4b).  
 
 
CBD (150 mg/kg) reduces TMEV-induced acute seizures  
 
at 4 h, but not at 9 h, posttreatment 
 
Acute seizure monitoring was conducted at 4 and 9 h post-CBD treatment in all 
the experiments described above. If the time to peak effect (TPE) of CBD in this model is 
less than 4 h posttreatment, we might not have detected any potential antiseizure effects 
of CBD with doses less than 180 mg/kg. Therefore, the TPE of CBD was investigated in 
male C57BL/6J mice using the 6 Hz psychomotor seizure test as previously described 
(Barton et al., 2001). The TPE for CBD was found to be 2 h post-CBD treatment, with a 
diminished efficacy at 4 h (unpublished data, Dr. Misty D. Smith, University of Utah). 
Therefore, to detect any beneficial effect of CBD treatment on seizures at the 4 h 
posttreatment observation time point, we analyzed the data for the two daily monitoring 




treatment in the groups treated with 22.5, 45, 90, 135, or 165 mg/kg of CBD compared to 
vehicle-treated control mice. However, mice treated with 150 mg/kg CBD had a 
significant reduction in the average number of seizures during the acute seizure activity 
period monitored at 4 h posttreatment (CBD: 0.5 ± 0.15, Vehicle: 1.45 ± 0.31, n = 20, 
p=0.0095; Data are presented as average seizures ± SEM.), but not at 9 h (CBD: 1.15 ± 
0.25, Vehicle: 1.55 ± 0.26, n = 20, p=0.2747. Data are presented as average seizures ± 
SEM.) (Figure 4.5). Likewise, the average cumulative seizure burden, calculated by 
analyzing seizures only at the 4 h post-CBD time point was significantly reduced in 150 
mg/kg CBD group at 6 and 7 dpi (Figure 4.5b). These data suggest that the doses of CBD 
investigated (22.5-165 mg/kg) might be effective in reducing TMEV-induced acute 





The experiments conducted here demonstrate that CBD (180 mg/kg) consistently 
reduced both the frequency and severity of acute behavioral seizures following TMEV 
infection, but the lower doses of CBD (ranging from 22.5 to 165 mg/kg) did not improve 
seizure outcome during the acute infection period. However, we found a significant 
reduction in frequency and severity of acute seizures monitored at 4 h post-CBD (150 
mg/kg) treatment, whereas these beneficial effects were not observed when the seizures 
were monitored at the 9 h post-CBD treatment. Based on this finding, and data suggesting 
that the TPE for C57BL/6J is 2 h in acute seizure models, future studies should evaluate 
seizure incidence in the TMEV model at or before the TPE. Other pharmacokinetic 




unknown and the detailed understanding of these parameters will be helpful in 
determining an optimum dosing paradigm of CBD for the treatment of TMEV-induced 
acute seizures.  
Acute seizures due to CNS infection greatly increase the probability for the 
development of chronic spontaneous seizures (Berg, 2008; Hesdorffer et al., 1998). It will 
be of utmost importance to investigate whether suppression of TMEV-induced acute 
behavioral seizures by CBD treatment (180 mg/kg) provides disease-modifying effects 
and can prevent the development of epilepsy in this model. Acute TMEV infection causes 
a robust increase in the levels of proinflammatory cytokines and chemokines as well as 
oxidative stress markers (Bhuyan et al., 2015; Kirkman et al., 2010), and CBD exerts 
antiinflammatory and antioxidant actions (Rosenberg et al., 2015). Therefore, the changes 
in the levels of the proinflammatory cytokines and oxidative stress markers, coincident 
with the changes in acute seizures due to CBD treatment, should be measured in future 
studies to assess the contribution of inflammation and oxidative stress in driving seizures 
in this model and also to assess the mechanism of action of CBD. 
The present study highlights the importance of the TMEV model of limbic 
epilepsy as a drug screening tool for the development of novel therapeutic approaches for 
the treatment of acute seizures as well as for the prevention of epileptogenesis. The 
efficacy of carbamazepine and valproate has been assessed in this model (Barker-Haliski 
et al., 2015). Valproate (200 mg/kg) and carbamazepine (20 mg/kg) given twice daily 
during the first week of TMEV infection did not decrease numbers of TMEV-infected 
mice developing acute seizures; however, valproate reduced the seizure severity (Barker-




developing seizures and the concomitant seizure burden, and decreased the latency to 
first seizure (Barker-Haliski et al., 2015). Thus, this model is refractory to at least one 
commonly used ASD. Given intense scientific and public interest in cannabinoid-based 
therapies for intractable epilepsies, thorough animal studies evaluating the safety and 
efficacy of CBD either alone or in combination with available ASDs in a battery of 
epilepsy models are highly desirable. In line with that goal, Dr. Misty D. Smith recently 
conducted an isobolographic analysis of CBD in combination with five mechanistically 
different ASDs (carbamazepine, clonazepam, levetiracetam, valproate, and lacosamide) 
in their ED50 combinations of 3:1, 1:1 and 1:3 to investigate their efficacy in preventing 
seizures in the 6 Hz model in CF1 mice. Only the 1:1 combination of CBD:levetiracetam 
showed synergistic effects in suppressing seizures among all the other combinations 
tested. Therefore, polytherapy using CBD and levetiracetam may provide superior control 
of seizures with minimal adverse effects because 1) there are diverse mechanisms of 
antiseizure actions of CBD and levetiracetam and 2) their complementary actions in 
reducing distinct sets of cytokines as levetiracetam reduces the levels of IL-1β (Kim et 
al., 2010) and CBD decreases expression of TNFα, IL-6, IL-2, IFNγ, IL-12p40, and IL-
17 (Burstein, 2015). Consistency of these findings should be evaluated using other 
models of epilepsy including the TMEV model.  
In conclusion, CBD (180 mg/kg) given twice daily intraperitoneally consistently 
reduces acute behavioral seizures induced by TMEV infection. The pharmacology of 
CBD in the TMEV model will be studied in detail by determining the pharmacokinetic 
parameters which will better inform future study design and by investigating 






Barker-Haliski, M.L., Dahle, E.J., Heck, T.D., Pruess, T.H., Vanegas, F., Wilcox, K.S., 
White, H.S., 2015. Evaluating an etiologically relevant platform for therapy 
development for temporal lobe epilepsy: effects of carbamazepine and valproic 
acid on acute seizures and chronic behavioral comorbidities in the Theiler's 
murine encephalomyelitis virus mouse model. J. Pharmacol. Exp. Ther. 353, 318-
329. 
 
Barton, M.E., Klein, B.D., Wolf, H.H., White, H.S., 2001. Pharmacological 
characterization of the 6 Hz psychomotor seizure model of partial epilepsy. 
Epilepsy Res. 47, 217-227. 
 
Berg, A.T., 2008. Risk of recurrence after a first unprovoked seizure. Epilepsia 49 Suppl 
1, 13-18. 
 
Bhuyan, P., Patel, D.C., Wilcox, K.S., Patel, M., 2015. Oxidative stress in murine 
Theiler's virus-induced temporal lobe epilepsy. Exp. Neurol. 271, 329-334. 
 
Boison, D., 2012. Adenosine dysfunction in epilepsy. Glia 60, 1234-1243. 
 
Burstein, S., 2015. Cannabidiol (CBD) and its analogs: a review of their effects on 
inflammation. Bioorg. Med. Chem. 23, 1377-1385. 
 
Carrier, E.J., Auchampach, J.A., Hillard, C.J., 2006. Inhibition of an equilibrative 
nucleoside transporter by cannabidiol: a mechanism of cannabinoid 
immunosuppression. Proc. Natl. Acad. Sci. U. S. A. 103, 7895-7900. 
 
Cusick, M.F., Libbey, J.E., Patel, D.C., Doty, D.J., Fujinami, R.S., 2013. Infiltrating 
macrophages are key to the development of seizures following virus infection. J. 
Virol. 87, 1849-1860. 
 
Friedman, D., Devinsky, O., 2015. Cannabinoids in the Treatment of Epilepsy. N. Engl. 
J. Med. 373, 1048-1058. 
 
Guilliams, K., Rosen, M., Buttram, S., Zempel, J., Pineda, J., Miller, B., Shoykhet, M., 
2013. Hypothermia for pediatric refractory status epilepticus. Epilepsia 54, 1586-
1594. 
 
Hasko, G., Cronstein, B.N., 2004. Adenosine: an endogenous regulator of innate 
immunity. Trends Immunol. 25, 33-39. 
 
Hegde, V.L., Nagarkatti, P.S., Nagarkatti, M., 2011. Role of myeloid-derived suppressor 
cells in amelioration of experimental autoimmune hepatitis following activation 





Hesdorffer, D.C., Logroscino, G., Cascino, G., Annegers, J.F., Hauser, W.A., 1998. Risk 
of unprovoked seizure after acute symptomatic seizure: effect of status 
epilepticus. Ann. Neurol. 44, 908-912. 
 
Kim, J.E., Choi, H.C., Song, H.K., Jo, S.M., Kim, D.S., Choi, S.Y., Kim, Y.I., Kang, 
T.C., 2010. Levetiracetam inhibits interleukin-1 beta inflammatory responses in 
the hippocampus and piriform cortex of epileptic rats. Neurosci. Lett. 471, 94-99. 
 
Kirkman, N.J., Libbey, J.E., Wilcox, K.S., White, H.S., Fujinami, R.S., 2010. Innate but 
not adaptive immune responses contribute to behavioral seizures following viral 
infection. Epilepsia 51, 454-464. 
 
Kozela, E., Lev, N., Kaushansky, N., Eilam, R., Rimmerman, N., Levy, R., Ben-Nun, A., 
Juknat, A., Vogel, Z., 2011. Cannabidiol inhibits pathogenic T cells, decreases 
spinal microglial activation and ameliorates multiple sclerosis-like disease in 
C57BL/6 mice. Br. J. Pharmacol. 163, 1507-1519. 
 
Libbey, J.E., Kennett, N.J., Wilcox, K.S., White, H.S., Fujinami, R.S., 2011. Interleukin-
6, produced by resident cells of the central nervous system and infiltrating cells, 
contributes to the development of seizures following viral infection. J. Virol. 85, 
6913-6922. 
 
Liou, G.I., Auchampach, J.A., Hillard, C.J., Zhu, G., Yousufzai, B., Mian, S., Khan, S., 
Khalifa, Y., 2008. Mediation of cannabidiol anti-inflammation in the retina by 
equilibrative nucleoside transporter and A2A adenosine receptor. Invest. 
Ophthalmol. Vis. Sci. 49, 5526-5531. 
 
Loewen, J.L., Barker-Haliski, M.L., Dahle, E.J., White, H.S., Wilcox, K.S., 2016. 
Neuronal injury, gliosis, and glial proliferation in two models of temporal lobe 
epilepsy. J. Neuropathol. Exp. Neurol. 75, 366-378. 
 
Mecha, M., Feliu, A., Inigo, P.M., Mestre, L., Carrillo-Salinas, F.J., Guaza, C., 2013. 
Cannabidiol provides long-lasting protection against the deleterious effects of 
inflammation in a viral model of multiple sclerosis: a role for A2A receptors. 
Neurobiol. Dis. 59, 141-150. 
 
Rosenberg, E.C., Tsien, R.W., Whalley, B.J., Devinsky, O., 2015. Cannabinoids and 
Epilepsy. Neurotherapeutics 12, 747-768. 
 
Scheirer, C.J., Ray, W.S., Hare, N., 1976. The analysis of ranked data derived from 
completely randomized factorial designs. Biometrics 32, 429-434. 
 
Smith, M.D., Wilcox, K.S., White, H.S., 2015. Abstract 1.215: Analysis of cannabidiol 






Stewart, K.A., Wilcox, K.S., Fujinami, R.S., White, H.S., 2010. Development of 
postinfection epilepsy after Theiler's virus infection of C57BL/6 mice. J. 
Neuropathol. Exp. Neurol. 69, 1210-1219. 
 
Sylantyev, S., Jensen, T.P., Ross, R.A., Rusakov, D.A., 2013. Cannabinoid- and 
lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter 
release at central synapses. Proc. Natl. Acad. Sci. U. S. A. 110, 5193-5198. 
 
Vezzani, A., French, J., Bartfai, T., Baram, T.Z., 2011. The role of inflammation in 
epilepsy. Nat. Rev. Neurol. 7, 31-40. 
 
Wang, Y., Liu, P.P., Li, L.Y., Zhang, H.M., Li, T., 2011. Hypothermia reduces brain 
edema, spontaneous recurrent seizure attack, and learning memory deficits in the 
kainic acid treated rats. CNS Neurosci. Ther. 17, 271-280. 
 
Wong, J.P., Saravolac, E.G., Clement, J.G., Nagata, L.P., 1997. Development of a murine 
hypothermia model for study of respiratory tract influenza virus infection. Lab. 



















Figure 4.1 Prophylactic treatment with 180 mg/kg CBD reduces average frequency and 
severity of TMEV-induced acute seizures. (a) Outline of prophylactic CBD treatment 
regimen. (b) Acute seizures were induced by handling the mice four times a day – during 
CBD/vehicle injections (7:00 AM, 7:00 PM) and during seizure monitoring (11:00 AM, 
4:00 PM). Seizure severity was video-monitored with the experimenter blinded to the 
treatment groups, scored based on a modified Racine scale ranging from stage 3 to 6, and 
depicted as a heat map using green, yellow, orange, and red colors corresponding to 
seizure scores in increasing order (DI, during injection; dpi, days postinfection). (c, d) 
Prophylactic CBD treatment significantly reduces seizure frequency (c) plotted as total 
numbers of seizures per mouse and seizure severity (d) as measured by average 
cumulative seizure burden during acute seizure period (3-8 dpi) in TMEV-infected mice. 
Each circle represents an individual mouse and the horizontal line indicates the average 
number of seizures per group. (e) Development of the first acute seizure is significantly 
delayed in CBD-treated mice compared to vehicle-treated mice. Statistics: unpaired t-test 






















Figure 4.2 Therapeutic treatment with CBD (180 mg/kg) reduces average frequency and 
severity of TMEV-induced acute seizures. (a) Outline of therapeutic CBD treatment 
regimen. (b) Acute seizures were induced by handling the mice four times a day – during 
CBD/vehicle injections (7:00 AM, 7:00 PM) and during seizure monitoring (11:00 AM, 
4:00 PM). Seizure severity was video-monitored with the experimenter blinded to the 
treatment groups, categorized based on modified Racine scale ranging from stage 3 to 6, 
and data depicted as a heat map using green, yellow, orange, and red colors 
corresponding to seizure scores in increasing order (DI, during injection; dpi, days 
postinfection). (c, d) Therapeutic CBD treatment significantly reduces seizure frequency 
(c) plotted as total numbers of seizures per mouse and seizure severity (d) as measured by 
average cumulative seizure burden during acute seizure period (3-8 dpi) compared to 
vehicle-treated TMEV-infected mice. Each circle represents an individual mouse and the 
horizontal line indicates the average number of seizures per group. (e) Development of 
the first seizure is not significantly different between treatment groups. Statistics: 













Figure 4.3 Only one dose of CBD (180 mg/kg; range of 22.5 to 180 mg/kg) reduces 
frequency and severity of TMEV-induced acute seizures. Five groups of mice (n = 10 per 
group) were infected with TMEV (2x105 PFU/mouse) and treated with either vehicle or 
different doses of CBD (22.5, 45, 90, and 180 mg/kg) i.p. every 12 h for 5 days starting at 
3 dpi. (a) CBD (180 mg/kg) treatment, but not the other doses, significantly reduces 
seizure frequency plotted as total numbers of seizures per mouse compared to vehicle as 
well as 22.5, 45, and 90 mg/kg CBD groups. Each circle indicates individual mouse and 
the horizontal line indicates average number of seizures per group. (b) Similarly, only 
180 mg/kg CBD reduces seizure severity as measured by average cumulative seizure 
burden compared to all the other treatment groups, but the treatment with the lower doses 
of CBD does not affect seizure severity. (c) Changes in the average weight of mice in 
each treatment group over acute infection period shows a significant reduction in 180 
mg/kg CBD treated mice compared to other treatment groups between 5-9 dpi. (d) Core 
body temperature of 180 mg/kg CBD-treated mice as measured immediately before CBD 
treatment (baseline) and at 15 min, 30 min, 1, 2, and 4 h posttreatment each day during 3-
7 dpi shows a significant reduction on 3 dpi compared to other days. Statistics: unpaired 
t-test (frequency), Scheirer-Ray-Hare test (severity), two-way ANOVA, (weight and 







Figure 4.4 Low doses of CBD have no effect on TMEV-induced acute seizures. Mice 
were infected with TMEV (2x105 PFU/mouse) and treated with either vehicle or CBD 
(135, 150, and 165 mg/kg) i.p. every 12 h for 5 days starting at 3 dpi. 135 mg/kg (a) as 
well as 150 and 165 mg/kg (b) CBD treatment does not reduce average frequency (upper 
panels) and intensity (lower panels) of TMEV-induced seizures. Data from two separate 








Figure 4.5 CBD (150 mg/kg) administration decreases TMEV-induced seizures 
monitored at 4 h post-CBD treatment but not at 9 h post-CBD treatment. (a) Analysis of 
seizures monitored at 4 h post-CBD treatment shows a significant reduction in the 
average number of seizures (upper panel) and the average cumulative seizure burden at 6 
and 7 dpi (lower panel) compared to the vehicle group. (b) CBD (150 mg/kg) treatment 
does not affect seizure endpoints measured at 9 h posttreatment. Statistics: unpaired t-test 



















The Theiler’s Murine Encephalitis Virus (TMEV) model is a recently developed 
CNS infection-induced animal model of temporal lobe epilepsy (TLE) crucial to our 
ability to investigate the cellular, molecular, and network level mechanisms implicated in 
seizure generation, propagation and transforming homeostatic neural circuits into 
epileptic circuits. The TMEV model also provides an important platform to test next-
generation therapeutics aimed at symptomatic seizure control (antiseizure) as well as for 
disease modification (antiepileptogenic). Previous studies have discovered that innate 
immune responses, mainly driven by the cytokines TNFα, IL-6 and complement protein 
C3, cause inflammatory reactions in the brains of TMEV-infected mice concurrently with 
acute behavioral seizures (Kirkman et al., 2010). Inflammation is known to contribute to 
oxidative stress and mitochondrial dysfunction (Morris and Berk, 2015), whereas the 
latter can cause injury by inducing inflammation, contributing to neurodegeneration, and 
inducing hyperexcitability (Naik and Dixit, 2011). Both inflammation and oxidative 
stress could therefore be both a cause and/or a consequence of brain damage and seizure 
activity. Further, CNS infections and mitochondrial disorders are associated with 
increased incidence of seizures and epilepsy in patients (Vezzani et al., 2016; Waldbaum 




neuronal injury and seizures; however, the details of the relationship between these 
factors have not been studied during TMEV infection-induced seizures and epilepsy. 
Therefore, the present studies investigated the occurrence of oxidative stress and 
inflammation in the hippocampus, a brain region known to generate limbic seizures, 
during the TMEV-induced acute seizure period and how inflammation could modulate 
acute seizures.  
 
 
Summary and implications of findings 
 
Our data show a strong correlation between impairment of redox status, a robust 
increase in proinflammatory markers, and acute behavioral seizures following TMEV 
infection. Among the numbers of cytokines elevated in the hippocampus during acute 
seizures, we studied TNFα and its receptors in depth for their contribution to 
hyperexcitability and seizures. TNFR1-mediated signaling of TNFα predominantly drives 
hyperexcitatory synaptic changes and contributes to seizure occurrence, since TNFR1-/- 
and TNFR1-/-TNFR2-/- mice are markedly resistant to developing TMEV-induced acute 
seizures. In contrast, TNFR2-mediated signaling of TNFα could be a part of an 
endogenous antiseizure mechanism, as the numbers and severity of seizures are worse in 
TNFR2-/- mice than in WT. Given the changes in other cytokines and oxidative stress 
markers, the mechanisms of seizure generation in this model are most likely 
multifactorial and interactions between additional underlying factors should be 
investigated further. Also, due to the observed increases in the levels of multiple 
proinflammatory cytokines, we also tested the efficacy of cannabidiol (CBD) which 




Rosenberg et al., 2015). CBD (180 mg/kg) effectively suppressed TMEV-induced acute 
seizures, however, the pharmacokinetic and pharmacodynamic properties of CBD in this 
model require further investigation.  
The present research has strong translational implications by targeting TNFRs in 
the brain for the treatment of acute seizures during infections and possibly for the 
prevention of epilepsies caused by infection and CNS inflammation. The mechanism by 
which TNFα causes hippocampal hyperexcitability through TNFR1 is not just limited to 
the TMEV model of epilepsy. Indeed, a proictogenic role of TNFR1-mediated signaling 
and an antiictogenic role of TNFR2-mediated signaling have also been reported in the 
kainic acid-induced model of epilepsy (Balosso et al., 2005; Weinberg et al., 2013). 
TNFRs have been proven to be successful targets for treating many peripheral 
inflammatory diseases, and several biologics targeting the TNF system in the CNS are 
under development (Fischer et al., 2015; McCoy and Tansey, 2008) which might be 
helpful to treat inflammation-induced TLE. Inhibition of other inflammatory pathways 
mediated by IL-1 receptor and Toll-like receptors also provides antiseizure effects in 
various seizure models, and therefore, suggests that targeting inflammation could be an 
important strategy to treat pharmacoresistant epilepsies (Vezzani et al., 2011b). In line 
with previous findings, our results further substantiate the role of inflammation in causing 
seizures. The present research also demonstrates the utilization of an animal model of 
infection-induced epilepsy in testing novel compounds that have antiinflammatory as 
well as antiseizure activities. CBD-based drugs are currently under clinical trials for the 
treatment of Dravet syndrome, Lennox-Gastaut syndrome and other intractable forms of 




results presented here by evaluating safety and antiseizure mechanisms of CBD that will 





Future experiments will be directed toward site-specific and conditional deletion 
of TNFR1 in excitatory neurons and other cell types using a TNFR1fl/fl mouse to 
investigate a causal link between enhanced TNFR1 signaling and network 
hyperexcitability. TNFR1fl/fl mice were obtained from Dr. George Kollias’ group (Van 
Hauwermeiren et al., 2013). The effects of TNFα on neural circuit functions depend on 
various factors, including the relative expression levels of TNFRs (TNFR1 and 2) in the 
tissue and the cell types expressing them. For example, astrocyte dysfunction occurs in 
many acquired epilepsies (Robel and Sontheimer, 2016; Steinhauser and Seifert, 2012) 
and TNFα signaling through activation of TNFR1 has been shown to decrease expression 
of the astrocyte glutamate transporter (GLT-1) (Carmen et al., 2009) and connexin-43 
(Morioka et al., 2015). Pathogenic levels of TNFα also induce lasting synaptic alterations 
and cognitive impairment through astrocytic TNFR1-mediated signaling (Habbas et al., 
2015). Thus, the role of TNFR1 signaling in astrocytes should be investigated and the use 
of the TNFR1fl/fl mouse will be instrumental for such studies. TMEV-infected mice have 
widespread astrogliosis in the hippocampus during the acute infection period (Loewen et 
al., 2016). In addition, TMEV-infected mice exhibit anxiety-like behavior and cognitive 
impairment (Umpierre et al., 2014). Whether signaling through the TNFR1 pathway in 
astrocytes contributes to such tripartite synaptic alterations should be explored. On the 




damage. Although the studies on TNFR2 agonists are limited, activation of signaling 
through TNFR2 has been shown to ameliorate oxidative stress-induced cell death in 
cultured dopaminergic neurons (Fischer et al., 2011). Thus, a combination of a TNFR1 
antagonist and TNFR2 agonist might be an effective strategy for preventing TMEV-
induced seizures. In addition, since the protein expression of TNFR2 decreases in the 
hippocampus during acute seizures following TMEV infection, the molecular 
mechanisms that regulate synthesis and cell surface expression of TNFR2 could be 
exploited to increase the level of TNFR2.  
Considering the intracortical method of TMEV infection used and the observed 
infiltration of macrophages into the brain (Cusick et al., 2013), the blood-brain barrier 
(BBB) of TMEV-infected mice could be compromised. BBB injury is a contributing 
factor to the development of epilepsy (van Vliet et al., 2007). Extravasation of albumin 
from plasma into the brain occurs following BBB damage and albumin activation of 
TGFβ receptors on astrocytes can cause astrocyte dysfunction by impairing the functions 
of glutamate transporters, gap junction proteins, and inwardly-rectifying potassium 
channel currents, thus leading to hyperexcitation (Ivens et al., 2007). Interestingly, TGFβ 
expression in the hippocampus correlates with TMEV-associated seizure activity (Libbey 
et al., 2008). Future studies should evaluate BBB damage and TGFβ signaling in 
regulating astrocyte-neuronal functions following TMEV infection. In addition, 
numerous other cytokines such as IL-6, IFNγ, and IL-1β are also upregulated in the 
hippocampus during TMEV-induced acute seizures. Given the involvement of IL-6, 
IFNγ, and IL-1β in neuronal excitability in other models of epilepsy (Getts et al., 2007; 




their interactions with TNFα following TMEV infection should be characterized. Such 





A large body of clinical evidence suggests that inflammation could be one of the 
driving factors in precipitating seizures and mediating epileptogenesis (Vezzani et al., 
2011a). For example: 1) autoimmune diseases such as lupus and celiac disease increase 
the risk for seizures (Devinsky et al., 2013), 2) febrile seizures, which can lead to 
epilepsy, are correlated with immunological changes and inflammation (Choy et al., 
2014), 3) epileptic conditions with a strong inflammatory component, such as 
Rasmussen’s encephalitis and paraneoplastic autoimmune encephalitis, are associated 
with seizures that are often resistant to antiseizure drugs (Davis and Dalmau, 2013), 4) 
CNS developmental conditions such as cortical dysplasia and tuberous sclerosis are also 
associated with brain inflammation and increased seizure susceptibility (Aronica and 
Crino, 2014), and 5) antiinflammatory therapies, for example, steroids, can prevent 
seizures in several intractable epilepsies (Vincent et al., 2010). Confirmative clinical 
studies linking specific inflammatory components with elevated seizure probability are 
required. Thus, animal models mimicking clinical aspects of inflammation-associated 
epilepsies, such as the TMEV model of limbic epilepsy, must be leveraged to identify 
molecular mechanisms that could be targeted for future pharmacotherapies.  
Several caveats must be considered before applying antiinflammatory treatment 
for the treatment of seizures and for intervening in the process of epileptogenesis. First, 




challenging, particularly under latent CNS infections. Chronic mild to moderate 
neuroinflammatory conditions may not reveal clinical symptoms for several years, as 
observed in neurodegenerative diseases (Frank-Cannon et al., 2009). Therefore, studies 
directed toward the development of biomarkers for CNS inflammation should be 
prioritized, as such biomarkers will be highly useful for a timely pharmacological 
intervention to prevent seizures and the development of subsequent epilepsy. Second, 
timing for the initiation of antiinflammatory therapies will require a detailed 
understanding of the purpose of inflammation under CNS pathologies associated with 
seizures. Inflammation can be a double-edged sword, as it is necessary for the resolution 
of the CNS insult and the clearance of infectious agents from the brain. It is not advisable 
to resort to the use of broad-spectrum antiinflammatory drugs for a prolonged period as 
that may also interfere with the beneficial functions of inflammatory mechanisms and 
may cause collateral CNS damage. The ideal strategy should be to reestablish 
homeostatic equilibrium between endogenous inflammatory and antiinflammatory 
mechanisms and future research should help to determine the factors crucial in 
maintaining the equilibrium between inflammatory processes. Finally, many antiseizure 
drugs can affect innate and adaptive immune functions (Marchi et al., 2014). Therefore, 
thorough animal studies must be conducted to evaluate interactions between antiseizure 
and antiinflammatory drugs before initiating a combination therapy in the clinic for the 
treatment of acute seizures and the prevention of epilepsy following infection. No doubt 
the TMEV model of TLE, which has greatly contributed to our understanding of 
infection-induced epilepsy, will be useful in the preclinical development of such novel 






Aronica, E., Crino, P.B., 2014. Epilepsy related to developmental tumors and 
malformations of cortical development. Neurotherapeutics 11, 251-268. 
 
Balosso, S., Ravizza, T., Perego, C., Peschon, J., Campbell, I.L., De Simoni, M.G., 
Vezzani, A., 2005. Tumor necrosis factor-alpha inhibits seizures in mice via p75 
receptors. Ann. Neurol. 57, 804-812. 
 
Burstein, S., 2015. Cannabidiol (CBD) and its analogs: a review of their effects on 
inflammation. Bioorg. Med. Chem. 23, 1377-1385. 
 
Carmen, J., Rothstein, J.D., Kerr, D.A., 2009. Tumor necrosis factor-alpha modulates 
glutamate transport in the CNS and is a critical determinant of outcome from viral 
encephalomyelitis. Brain Res. 1263, 143-154. 
 
Choy, M., Dube, C.M., Ehrengruber, M., Baram, T.Z., 2014. Inflammatory processes, 
febrile seizures, and subsequent epileptogenesis. Epilepsy Curr. 14, 15-22. 
 
Cusick, M.F., Libbey, J.E., Patel, D.C., Doty, D.J., Fujinami, R.S., 2013. Infiltrating 
macrophages are key to the development of seizures following virus infection. J. 
Virol. 87, 1849-1860. 
 
Davis, R., Dalmau, J., 2013. Autoimmunity, seizures, and status epilepticus. Epilepsia 54 
Suppl 6, 46-49. 
 
Devinsky, O., Schein, A., Najjar, S., 2013. Epilepsy associated with systemic 
autoimmune disorders. Epilepsy Curr. 13, 62-68. 
 
Fischer, R., Kontermann, R., Maier, O., 2015. Targeting sTNF/TNFR1 signaling as a new 
therapeutic strategy. Antibodies 4, 48-70. 
 
Fischer, R., Maier, O., Siegemund, M., Wajant, H., Scheurich, P., Pfizenmaier, K., 2011. 
A TNF receptor 2 selective agonist rescues human neurons from oxidative stress-
induced cell death. PLoS One 6, e27621. 
 
Frank-Cannon, T.C., Alto, L.T., McAlpine, F.E., Tansey, M.G., 2009. Does 
neuroinflammation fan the flame in neurodegenerative diseases? Mol. 
Neurodegener. 4, 47. 
 
Friedman, D., Devinsky, O., 2015. Cannabinoids in the Treatment of Epilepsy. N. Engl. 
J. Med. 373, 1048-1058. 
 
Getts, D.R., Matsumoto, I., Muller, M., Getts, M.T., Radford, J., Shrestha, B., Campbell, 
I.L., King, N.J., 2007. Role of IFN-gamma in an experimental murine model of 




Habbas, S., Santello, M., Becker, D., Stubbe, H., Zappia, G., Liaudet, N., Klaus, F.R., 
Kollias, G., Fontana, A., Pryce, C.R., Suter, T., Volterra, A., 2015. 
Neuroinflammatory TNFalpha Impairs Memory via Astrocyte Signaling. Cell 
163, 1730-1741. 
 
Ivens, S., Kaufer, D., Flores, L.P., Bechmann, I., Zumsteg, D., Tomkins, O., Seiffert, E., 
Heinemann, U., Friedman, A., 2007. TGF-beta receptor-mediated albumin uptake 
into astrocytes is involved in neocortical epileptogenesis. Brain 130, 535-547. 
 
Kirkman, N.J., Libbey, J.E., Wilcox, K.S., White, H.S., Fujinami, R.S., 2010. Innate but 
not adaptive immune responses contribute to behavioral seizures following viral 
infection. Epilepsia 51, 454-464. 
 
Libbey, J.E., Kirkman, N.J., Smith, M.C., Tanaka, T., Wilcox, K.S., White, H.S., 
Fujinami, R.S., 2008. Seizures following picornavirus infection. Epilepsia 49, 
1066-1074. 
 
Loewen, J.L., Barker-Haliski, M.L., Dahle, E.J., White, H.S., Wilcox, K.S., 2016. 
Neuronal injury, gliosis, and glial proliferation in two models of temporal lobe 
epilepsy. J. Neuropathol. Exp. Neurol. 75, 366-378. 
 
Marchi, N., Granata, T., Janigro, D., 2014. Inflammatory pathways of seizure disorders. 
Trends Neurosci. 37, 55-65. 
 
McCoy, M.K., Tansey, M.G., 2008. TNF signaling inhibition in the CNS: implications 
for normal brain function and neurodegenerative disease. J. Neuroinflammation 5, 
45. 
 
Morioka, N., Zhang, F.F., Nakamura, Y., Kitamura, T., Hisaoka-Nakashima, K., Nakata, 
Y., 2015. Tumor necrosis factor-mediated downregulation of spinal astrocytic 
connexin43 leads to increased glutamatergic neurotransmission and neuropathic 
pain in mice. Brain. Behav. Immun. 49, 293-310. 
 
Morris, G., Berk, M., 2015. The many roads to mitochondrial dysfunction in 
neuroimmune and neuropsychiatric disorders. BMC Med. 13, 68. 
 
Naik, E., Dixit, V.M., 2011. Mitochondrial reactive oxygen species drive 
proinflammatory cytokine production. J. Exp. Med. 208, 417-420. 
 
Robel, S., Sontheimer, H., 2016. Glia as drivers of abnormal neuronal activity. Nat. 
Neurosci. 19, 28-33. 
 
Rosenberg, E.C., Tsien, R.W., Whalley, B.J., Devinsky, O., 2015. Cannabinoids and 
Epilepsy. Neurotherapeutics 12, 747-768. 
 




I.L., 2003. Profound increase in sensitivity to glutamatergic- but not cholinergic 
agonist-induced seizures in transgenic mice with astrocyte production of IL-6. J. 
Neurosci. Res. 73, 176-187. 
 
Steinhauser, C., Seifert, G., 2012. Astrocyte dysfunction in epilepsy, in: Noebels, J.L., 
Avoli, M., Rogawski, M.A., Olsen, R.W., Delgado-Escueta, A.V. (Eds.), Jasper's 
Basic Mechanisms of the Epilepsies, 4th ed, Bethesda (MD). 
 
Umpierre, A.D., Remigio, G.J., Dahle, E.J., Bradford, K., Alex, A.B., Smith, M.D., West, 
P.J., White, H.S., Wilcox, K.S., 2014. Impaired cognitive ability and anxiety-like 
behavior following acute seizures in the Theiler's virus model of temporal lobe 
epilepsy. Neurobiol. Dis. 64, 98-106. 
 
Van Hauwermeiren, F., Armaka, M., Karagianni, N., Kranidioti, K., Vandenbroucke, 
R.E., Loges, S., Van Roy, M., Staelens, J., Puimege, L., Palagani, A., Berghe, 
W.V., Victoratos, P., Carmeliet, P., Libert, C., Kollias, G., 2013. Safe TNF-based 
antitumor therapy following p55TNFR reduction in intestinal epithelium. J. Clin. 
Invest. 123, 2590-2603. 
 
van Vliet, E.A., da Costa Araujo, S., Redeker, S., van Schaik, R., Aronica, E., Gorter, 
J.A., 2007. Blood-brain barrier leakage may lead to progression of temporal lobe 
epilepsy. Brain 130, 521-534. 
 
Vezzani, A., French, J., Bartfai, T., Baram, T.Z., 2011a. The role of inflammation in 
epilepsy. Nat. Rev. Neurol. 7, 31-40. 
 
Vezzani, A., Fujinami, R.S., White, H.S., Preux, P.M., Blumcke, I., Sander, J.W., 
Loscher, W., 2016. Infections, inflammation and epilepsy. Acta Neuropathol. 131, 
211-234. 
 
Vezzani, A., Maroso, M., Balosso, S., Sanchez, M.A., Bartfai, T., 2011b. IL-1 
receptor/Toll-like receptor signaling in infection, inflammation, stress and 
neurodegeneration couples hyperexcitability and seizures. Brain. Behav. Immun. 
25, 1281-1289. 
 
Vincent, A., Irani, S.R., Lang, B., 2010. The growing recognition of immunotherapy-
responsive seizure disorders with autoantibodies to specific neuronal proteins. 
Curr. Opin. Neurol. 23, 144-150. 
 
Waldbaum, S., Patel, M., 2010. Mitochondria, oxidative stress, and temporal lobe 
epilepsy. Epilepsy Res. 88, 23-45. 
 
Weinberg, M.S., Blake, B.L., McCown, T.J., 2013. Opposing actions of hippocampus 
TNFalpha receptors on limbic seizure susceptibility. Exp. Neurol. 247, 429-437. 
 
 
